1
|
Ferri N, De Martin S, Stuart J, Traversa S, Folli F, Pappagallo M, O'Gorman C, Guidetti C, Mattarei A, Inturrisi CE, Manfredi PL. Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism. Drugs R D 2024; 24:51-68. [PMID: 38010591 PMCID: PMC11035515 DOI: 10.1007/s40268-023-00450-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/02/2023] [Indexed: 11/29/2023] Open
Abstract
BACKGROUND AND OBJECTIVE Esmethadone (dextromethadone; d-methadone; S-methadone (+)-methadone; REL-1017) is the opioid inactive dextro-isomer of racemic methadone. Esmethadone is a low potency N-methyl-D-aspartate (NMDA) receptor channel blocker with higher affinity for GluN2D subtypes. Esmethadone showed robust, rapid, and sustained antidepressant effects in patients with major depressive disorder (MDD) with inadequate response to ongoing serotonergic antidepressant treatment. METHODS Here we described the results of in vitro and phase 1 clinical trials aimed at investigating the esmethadone metabolism and possible drug-drug interactions. RESULTS Esmethadone is primarily metabolized to EDDP (2-ethylene-1,5-dimethyl-3,3-diphenylpyrrolidine) by multiple enzymes, including CYP3A4/5 and CYP2B6. In vitro studies showed that esmethadone inhibits CYP2D6 with IC50 of 9.6 μM and is an inducer of CYP3A4/5. The clinical relevance of the inhibition of CYP2D6 and the induction of CYP3A4 were investigated by co-administering esmethadone and dextromethorphan (a substrate for CYP2D6) or midazolam (a substrate for CYP3A4) in healthy volunteers. The administration of esmethadone at the dosage of 75 mg (which is the loading dose administered to patients in MDD clinical trials) significantly increased the exposure (AUC) of both dextromethorphan and its metabolite dextrorphan by 2.71 and 3.11-fold, respectively. Esmethadone did not modify the pharmacokinetic profile of midazolam, while it increased Cmax and AUC of its metabolite 1'-hydroxymidazolam by 2.4- and 3.8-fold, respectively. A second study evaluated the effect of the CYP3A4 inhibitor cobicistat on the pharmacokinetics of esmethadone. Cobicistat slightly increase (+32%) the total exposure (AUC0-inf) of esmethadone. CONCLUSIONS In summary, esmethadone demonstrated a negligible effect on CYP3A4 induction and its metabolism was not meaningfully affected by strong CYP3A4 inhibitors while it increased exposure of CYP2D6-metabolized drugs.
Collapse
Affiliation(s)
- Nicola Ferri
- Department of Medicine-DIMED, University of Padua, 35122, Padua, Italy.
- Veneto Institute of Molecular Medicine, Via Giuseppe Orus 2, 35129, Padua, Italy.
| | - Sara De Martin
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, 35122, Padua, Italy
| | - James Stuart
- Relmada Therapeutics, Coral Gables, FL, 33134, USA
| | | | - Franco Folli
- Department of Health Sciences, University of Milan, 20122, Milan, Italy
| | | | | | - Clotilde Guidetti
- Child and Adolescent Neuropsychiatry Unit, Department of Neuroscience, Bambino Pediatric Hospital, IRCCS, Rome, Italy
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, 35122, Padua, Italy
| | | | | |
Collapse
|
2
|
Di Marco G, Gherardi G, De Mario A, Piazza I, Baraldo M, Mattarei A, Blaauw B, Rizzuto R, De Stefani D, Mammucari C. The mitochondrial ATP-dependent potassium channel (mitoK ATP) controls skeletal muscle structure and function. Cell Death Dis 2024; 15:58. [PMID: 38233399 PMCID: PMC10794173 DOI: 10.1038/s41419-024-06426-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Revised: 12/20/2023] [Accepted: 01/02/2024] [Indexed: 01/19/2024]
Abstract
MitoKATP is a channel of the inner mitochondrial membrane that controls mitochondrial K+ influx according to ATP availability. Recently, the genes encoding the pore-forming (MITOK) and the regulatory ATP-sensitive (MITOSUR) subunits of mitoKATP were identified, allowing the genetic manipulation of the channel. Here, we analyzed the role of mitoKATP in determining skeletal muscle structure and activity. Mitok-/- muscles were characterized by mitochondrial cristae remodeling and defective oxidative metabolism, with consequent impairment of exercise performance and altered response to damaging muscle contractions. On the other hand, constitutive mitochondrial K+ influx by MITOK overexpression in the skeletal muscle triggered overt mitochondrial dysfunction and energy default, increased protein polyubiquitination, aberrant autophagy flux, and induction of a stress response program. MITOK overexpressing muscles were therefore severely atrophic. Thus, the proper modulation of mitoKATP activity is required for the maintenance of skeletal muscle homeostasis and function.
Collapse
Affiliation(s)
- Giulia Di Marco
- Department of Biomedical Sciences, University of Padova, Padova, Italy
| | - Gaia Gherardi
- Department of Biomedical Sciences, University of Padova, Padova, Italy
| | - Agnese De Mario
- Department of Biomedical Sciences, University of Padova, Padova, Italy
| | - Ilaria Piazza
- Department of Biomedical Sciences, University of Padova, Padova, Italy
| | | | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Bert Blaauw
- Department of Biomedical Sciences, University of Padova, Padova, Italy
- Venetian Institute of Molecular Medicine, Padova, Italy
- Myology Center (CIR-Myo), University of Padova, Padova, Italy
| | - Rosario Rizzuto
- Department of Biomedical Sciences, University of Padova, Padova, Italy
- Myology Center (CIR-Myo), University of Padova, Padova, Italy
| | - Diego De Stefani
- Department of Biomedical Sciences, University of Padova, Padova, Italy
| | - Cristina Mammucari
- Department of Biomedical Sciences, University of Padova, Padova, Italy.
- Myology Center (CIR-Myo), University of Padova, Padova, Italy.
| |
Collapse
|
3
|
Bernardotto S, Frasson I, Faravelli S, Morelli A, Schiavon E, Moscatiello GY, Violatto MB, Pinnola A, Canciani A, Mattarei A, Rossi G, Brini M, Pasetto L, Bonetto V, Bigini P, Forneris F, Richter SN, Morpurgo M. Efficient SARS-CoV-2 infection antagonization by rhACE2 ectodomain multimerized onto the Avidin-Nucleic-Acid-NanoASsembly. Biomaterials 2023; 303:122394. [PMID: 38007919 DOI: 10.1016/j.biomaterials.2023.122394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2023] [Revised: 10/18/2023] [Accepted: 11/09/2023] [Indexed: 11/28/2023]
Abstract
Nanodecoy systems based on analogues of viral cellular receptors assembled onto fluid lipid-based membranes of nano/extravescicles are potential new tools to complement classic therapeutic or preventive antiviral approaches. The need for lipid-based membranes for transmembrane receptor anchorage may pose technical challenges along industrial translation, calling for alternative geometries for receptor multimerization. Here we developed a semisynthetic self-assembling SARS-CoV-2 nanodecoy by multimerizing the biotin labelled virus cell receptor -ACE2- ectodomain onto a poly-avidin nanoparticle (NP) based on the Avidin-Nucleic-Acid-NanoASsembly-ANANAS. The ability of the assembly to prevent SARS-CoV-2 infection in human lung cells and the affinity of the ACE2:viral receptor-binding domain (RBD) interaction were measured at different ACE2:NP ratios. At ACE2:NP = 30, 90 % SARS-CoV-2 infection inhibition at ACE2 nanomolar concentration was registered on both Wuhan and Omicron variants, with ten-fold higher potency than the monomeric protein. Lower and higher ACE2 densities were less efficient suggesting that functional recognition between multi-ligand NPs and multi-receptor virus surfaces requires optimal geometrical relationships. In vivo studies in mice showed that the biodistribution and safety profiles of the nanodecoy are potentially suitable for preventing viral infection upon nasal instillation. Viral receptor multimerization using ANANAS is a convenient process which, in principle, could be rapidly adapted to counteract also other viral infections.
Collapse
Affiliation(s)
- Simone Bernardotto
- Pharmaceutical and Pharmacological Sciences Dept (DSF), University of Padova, Via Marzolo, 5. 35131, Padova, Italy
| | - Ilaria Frasson
- Department of Molecular Medicine (DMM), University of Padova, Via A. Gabelli, 63, 35121, Padova, Italy
| | - Silvia Faravelli
- The Armenise-Harvard Laboratory of Structural Biology, Dept. Biology and Biotechnology, University of Pavia, Via Ferrata 9/A, 27100, Pavia, Italy
| | - Annalisa Morelli
- Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy, Via Mario Negri 2, 20156, Milano, Italy; Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy
| | - Elisa Schiavon
- Pharmaceutical and Pharmacological Sciences Dept (DSF), University of Padova, Via Marzolo, 5. 35131, Padova, Italy
| | - Giulia Yuri Moscatiello
- Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy, Via Mario Negri 2, 20156, Milano, Italy
| | - Martina Bruna Violatto
- Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy, Via Mario Negri 2, 20156, Milano, Italy
| | - Alberta Pinnola
- The Armenise-Harvard Laboratory of Structural Biology, Dept. Biology and Biotechnology, University of Pavia, Via Ferrata 9/A, 27100, Pavia, Italy
| | - Anselmo Canciani
- The Armenise-Harvard Laboratory of Structural Biology, Dept. Biology and Biotechnology, University of Pavia, Via Ferrata 9/A, 27100, Pavia, Italy
| | - Andrea Mattarei
- Pharmaceutical and Pharmacological Sciences Dept (DSF), University of Padova, Via Marzolo, 5. 35131, Padova, Italy
| | - Gianpaolo Rossi
- Department of Medicine (DIMED), University of Padova, Via Giustiniani, 2, 35131, Padova, Italy
| | - Marisa Brini
- Department of Biology (DIBIO), Viale G. Colombo, 3, 35131, Padova, Italy
| | - Laura Pasetto
- Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy, Via Mario Negri 2, 20156, Milano, Italy
| | - Valentina Bonetto
- Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy, Via Mario Negri 2, 20156, Milano, Italy
| | - Paolo Bigini
- Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy, Via Mario Negri 2, 20156, Milano, Italy
| | - Federico Forneris
- The Armenise-Harvard Laboratory of Structural Biology, Dept. Biology and Biotechnology, University of Pavia, Via Ferrata 9/A, 27100, Pavia, Italy
| | - Sara N Richter
- Department of Molecular Medicine (DMM), University of Padova, Via A. Gabelli, 63, 35121, Padova, Italy; Microbiology and Virology Unit, Padua University Hospital, 35121, Padua, Italy.
| | - Margherita Morpurgo
- Pharmaceutical and Pharmacological Sciences Dept (DSF), University of Padova, Via Marzolo, 5. 35131, Padova, Italy.
| |
Collapse
|
4
|
Fava M, Stahl SM, De Martin S, Mattarei A, Bettini E, Comai S, Alimonti A, Bifari F, Pani L, Folli F, Guidetti C, Furlan A, Sgrignani J, Locatelli P, Cavalli A, O’Gorman C, Traversa S, Inturrisi CE, Pappagallo M, Manfredi PL. Esmethadone-HCl (REL-1017): a promising rapid antidepressant. Eur Arch Psychiatry Clin Neurosci 2023; 273:1463-1476. [PMID: 36890259 PMCID: PMC10465385 DOI: 10.1007/s00406-023-01571-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/28/2022] [Accepted: 02/13/2023] [Indexed: 03/10/2023]
Abstract
This review article presents select recent studies that form the basis for the development of esmethadone into a potential new drug. Esmethadone is a promising member of the pharmacological class of uncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonists that have shown efficacy for major depressive disorder (MDD) and other diseases and disorders, such as Alzheimer's dementia and pseudobulbar affect. The other drugs in the novel class of NMDAR antagonists with therapeutic uses that are discussed for comparative purposes in this review are esketamine, ketamine, dextromethorphan, and memantine. We present in silico, in vitro, in vivo, and clinical data for esmethadone and other uncompetitive NMDAR antagonists that may advance our understanding of the role of these receptors in neural plasticity in health and disease. The efficacy of NMDAR antagonists as rapid antidepressants may advance our understanding of the neurobiology of MDD and other neuropsychiatric diseases and disorders.
Collapse
Affiliation(s)
- Maurizio Fava
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114 USA
| | - Stephen M. Stahl
- Department of Psychiatry, VAMC (SD), University of California, San Diego, La Jolla, CA 92093 USA
- Neuroscience Education Institute, Carlsbad, CA 92008 USA
| | - Sara De Martin
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, 35122 Padua, Italy
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, 35122 Padua, Italy
| | - Ezio Bettini
- In Vitro Pharmacology Department, Aptuit, an Evotec Company, 37135 Verona, Italy
| | - Stefano Comai
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, 35122 Padua, Italy
- Department of Biomedical Sciences, University of Padua, 35122 Padua, Italy
- Department of Psychiatry, McGill University, Montreal, QC H3A 1A1 Canada
| | - Andrea Alimonti
- Department of Health Sciences and Technology, ETH Zurich, 8092 Zurich, Switzerland
- Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), 6500 Bellinzona, Switzerland
- Università della Svizzera Italiana, 6900 Lugano, Switzerland
- Veneto Institute of Molecular Medicine, 35129 Padua, Italy
- Department of Medicine—DIMED, University of Padua, 35122 Padua, Italy
| | - Francesco Bifari
- Department of Medical Biotechnology and Translational Medicine, University of Milan, 20122 Milan, Italy
| | - Luca Pani
- Relmada Therapeutics, Coral Gables, FL 33134 USA
- Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Miami, Miami, FL 33146 USA
- Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy
| | - Franco Folli
- Department of Health Sciences, University of Milan, 20122 Milan, Italy
| | - Clotilde Guidetti
- Child and Adolescent Neuropsychiatry Unit, Department of Neuroscience, Bambino Gesù Pediatric Hospital, 00165 Rome, Italy
| | - Alberto Furlan
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, 35122 Padua, Italy
| | - Jacopo Sgrignani
- Institute for Research in Biomedicine (IRB), Università della Svizzera Italiana (USI), 6500 Bellinzona, Switzerland
| | - Patrizia Locatelli
- Institute for Research in Biomedicine (IRB), Università della Svizzera Italiana (USI), 6500 Bellinzona, Switzerland
| | - Andrea Cavalli
- Institute for Research in Biomedicine (IRB), Università della Svizzera Italiana (USI), 6500 Bellinzona, Switzerland
- Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland
| | | | | | | | | | | |
Collapse
|
5
|
Shram MJ, Henningfield JE, Apseloff G, Gorodetzky CW, De Martin S, Vocci FL, Sapienza FL, Kosten TR, Huston J, Buchhalter A, Ashworth J, Lanier R, Folli F, Mattarei A, Guidetti C, Comai S, O'Gorman C, Traversa S, Inturrisi CE, Manfredi PL, Pappagallo M. The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users. Transl Psychiatry 2023; 13:192. [PMID: 37286536 DOI: 10.1038/s41398-023-02473-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Revised: 05/02/2023] [Accepted: 05/12/2023] [Indexed: 06/09/2023] Open
Abstract
Esmethadone (REL-1017) is the opioid-inactive dextro-isomer of methadone and a low-affinity, low-potency uncompetitive NMDA receptor antagonist. In a Phase 2, randomized, double-blind, placebo-controlled trial, esmethadone showed rapid, robust, and sustained antidepressant effects. Two studies were conducted to evaluate the abuse potential of esmethadone. Each study utilized a randomized, double-blind, active-, and placebo-controlled crossover design to assess esmethadone compared with oxycodone (Oxycodone Study) or ketamine (Ketamine Study) in healthy recreational drug users. Esmethadone 25 mg (proposed therapeutic daily dose), 75 mg (loading dose), and 150 mg (Maximum Tolerated Dose) were evaluated in each study. Positive controls were oral oxycodone 40 mg and intravenous ketamine 0.5 mg/kg infused over 40 min. The Ketamine study included oral dextromethorphan 300 mg as an exploratory comparator. The primary endpoint was maximum effect (Emax) for Drug Liking, assessed using a bipolar 100-point visual analog scale (VAS). A total of 47 and 51 participants completed the Oxycodone Study and the Ketamine Study, respectively (Completer Population). In both studies, esmethadone doses ranging from therapeutic (25 mg) to 6 times therapeutic (150 mg) had a meaningful and statistically significantly (p < 0.001) lower Drug Liking VAS Emax compared with the positive control. Results were consistent for all secondary endpoints in both studies. In both studies, all doses of esmethadone were statistically equivalent to placebo on Drug Liking VAS Emax (p < 0.05). In the Ketamine Study, Drug Liking VAS Emax scores for esmethadone at all tested doses were significantly lower vs. dextromethorphan (p < 0.05) (exploratory endpoint). These studies indicate no meaningful abuse potential for esmethadone at all tested doses.
Collapse
Affiliation(s)
| | | | | | - Charles W Gorodetzky
- Relmada Therapeutics, Coral Gables, FL, USA
- Consultant in Pharmaceutical Medicine, Kansas City, MO, USA
| | - Sara De Martin
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Frank L Vocci
- Relmada Therapeutics, Coral Gables, FL, USA
- Friends Research Institute, Baltimore, MD, USA
| | - Frank L Sapienza
- Relmada Therapeutics, Coral Gables, FL, USA
- The Drug and Chemical Advisory Group LLC, Fairfax, VA, USA
| | - Thomas R Kosten
- Relmada Therapeutics, Coral Gables, FL, USA
- Baylor College of Medicine, MD Anderson Cancer Center, University of Houston, Houston, TX, USA
| | | | | | | | | | - Franco Folli
- Department of Health Science, University of Milan, Milan, Italy
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Clotilde Guidetti
- Child and Adolescent Neuropsychiatry Unit, Department of Neuroscience, Bambino Pediatric Hospital, IRCCS, Rome, Italy
| | - Stefano Comai
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | | | | | | | | | | |
Collapse
|
6
|
Parrasia S, Rossa A, Roncaglia N, Mattarei A, Honisch C, Szabò I, Ruzza P, Biasutto L. DA7R: A 7-Letter Zip Code to Target PDAC. Pharmaceutics 2023; 15:pharmaceutics15051508. [PMID: 37242749 DOI: 10.3390/pharmaceutics15051508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2023] [Revised: 04/28/2023] [Accepted: 05/11/2023] [Indexed: 05/28/2023] Open
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, and is among the most aggressive and still incurable cancers. Innovative and successful therapeutic strategies are extremely needed. Peptides represent a versatile and promising tool to achieve tumor targeting, thanks to their ability to recognize specific target proteins (over)expressed on the surface of cancer cells. A7R is one such peptide, binding neuropilin-1 (NRP-1) and VEGFR2. Since PDAC expresses these receptors, the aim of this study was to test if A7R-drug conjugates could represent a PDAC-targeting strategy. PAPTP, a promising mitochondria-targeted anticancer compound, was selected as the cargo for this proof-of-concept study. Derivatives were designed as prodrugs, using a bioreversible linker to connect PAPTP to the peptide. Both the retro-inverso (DA7R) and the head-to-tail cyclic (cA7R) protease-resistant analogs of A7R were tested, and a tetraethylene glycol chain was introduced to improve solubility. Uptake of a fluorescent DA7R conjugate, as well as of the PAPTP-DA7R derivative into PDAC cell lines was found to be related to the expression levels of NRP-1 and VEGFR2. Conjugation of DA7R to therapeutically active compounds or nanovehicles might allow PDAC-targeted drug delivery, improving the efficacy of the therapy and reducing off-target effects.
Collapse
Affiliation(s)
- Sofia Parrasia
- Department of Biology, University of Padova, Viale G. Colombo 3, 35131 Padova, Italy
| | - Andrea Rossa
- Department of Chemical Sciences, University of Padova, Via F. Marzolo 1, 35131 Padova, Italy
| | - Nicola Roncaglia
- Department of Chemical Sciences, University of Padova, Via F. Marzolo 1, 35131 Padova, Italy
- CNR Institute of Biomolecular Chemistry, Padua Unit, Via F. Marzolo 1, 35131 Padova, Italy
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via F. Marzolo 5, 35131 Padova, Italy
| | - Claudia Honisch
- CNR Institute of Biomolecular Chemistry, Padua Unit, Via F. Marzolo 1, 35131 Padova, Italy
| | - Ildikò Szabò
- Department of Biology, University of Padova, Viale G. Colombo 3, 35131 Padova, Italy
| | - Paolo Ruzza
- CNR Institute of Biomolecular Chemistry, Padua Unit, Via F. Marzolo 1, 35131 Padova, Italy
| | - Lucia Biasutto
- CNR Neuroscience Institute, Padua Unit, Viale G. Colombo 3, 35131 Padova, Italy
| |
Collapse
|
7
|
Guidetti C, Serra G, Pani L, Pappagallo M, Maglio G, Martin SD, Mattarei A, Folli F, Manfredi PL, Fava M. Subanalysis of Subjective Cognitive Measures From a Phase 2, Double-Blind, Randomized Trial of REL-1017 in Patients With Major Depressive Disorder. Prim Care Companion CNS Disord 2023; 25. [PMID: 36821775 DOI: 10.4088/pcc.22m03267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023] Open
Abstract
Objective: Improvement of cognitive function in patients with major depressive disorder (MDD) is an important treatment outcome. REL-1017 (esmethadone HCl) is a novel N-methyl-d-aspartate receptor (NMDAR) channel blocker and a potentially rapidly acting antidepressant. The objective of this study was to define the effects of REL-1017 on subjective cognitive measures in patients with MDD. Methods: Post hoc analysis was conducted of subjective cognitive measures from the Montgomery-Asberg Depression Rating Scale (MADRS) and the Symptoms of Depression Questionnaire (SDQ) from a randomized, double-blind, placebo-controlled, Phase 2a study. The study, designed to assess the safety, tolerability, and efficacy of 2 dosages (25 mg and 50 mg) of REL-1017 as an adjunctive treatment in patients with MDD unresponsive to standard antidepressants, included 62 patients. We analyzed subjective cognitive measures derived from the MADRS and SDQ scales at baseline and up to day 14, 7 days after the last dose of study drug. We developed 2 composite indexes that included subjective cognitive measures selected from the MADRS and SDQ. Results: The subanalysis of single measures and the 2 composite indexes derived from the MADRS and SDQ measures showed clinically meaningful and statistically significant improvements in cognitive function (P < .05). Conclusions: In a Phase 2a clinical trial, REL-1017 improved subjective measures of cognitive impairment, in addition to improving total MADRS and SDQ scores. These results need to be confirmed in larger and longer studies in MDD that include objective measures of cognitive function. Phase 3 studies of REL-1017 for MDD are currently underway. Clinical Trials Registration: ClinicalTrials.gov identifier: NCT03051256.
Collapse
Affiliation(s)
- Clotilde Guidetti
- Child and Adolescent Neuropsychiatry Unit, Department of Neuroscience, Bambino Pediatric Hospital, IRCCS, Rome, Italy
| | - Giulia Serra
- Child and Adolescent Neuropsychiatry Unit, Department of Neuroscience, Bambino Pediatric Hospital, IRCCS, Rome, Italy
| | - Luca Pani
- Department of Psychiatry and Behavioral Sciences, University of Miami, School of Medicine, Miami, Florida.,Relmada Therapeutics, Coral Gables, Florida
| | - Marco Pappagallo
- Relmada Therapeutics, Coral Gables, Florida.,Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, New York
| | - Gino Maglio
- Child and Adolescent Neuropsychiatry Unit, Department of Neuroscience, Bambino Pediatric Hospital, IRCCS, Rome, Italy
| | - Sara De Martin
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Franco Folli
- Department of Health Science, University of Milan, Milan, Italy
| | - Paolo L Manfredi
- Relmada Therapeutics, Coral Gables, Florida.,Corresponding author: Paolo L. Manfredi, MD, Relmada Therapeutics, 2222 Ponce de Leon Blvd Floor 3, Coral Gables, FL 33134
| | - Maurizio Fava
- Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts
| |
Collapse
|
8
|
Marchioretti C, Zanetti G, Pirazzini M, Gherardi G, Nogara L, Andreotti R, Martini P, Marcucci L, Canato M, Nath SR, Zuccaro E, Chivet M, Mammucari C, Pacifici M, Raffaello A, Rizzuto R, Mattarei A, Desbats MA, Salviati L, Megighian A, Sorarù G, Pegoraro E, Belluzzi E, Pozzuoli A, Biz C, Ruggieri P, Romualdi C, Lieberman AP, Babu GJ, Sandri M, Blaauw B, Basso M, Pennuto M. Defective excitation-contraction coupling and mitochondrial respiration precede mitochondrial Ca 2+ accumulation in spinobulbar muscular atrophy skeletal muscle. Nat Commun 2023; 14:602. [PMID: 36746942 PMCID: PMC9902403 DOI: 10.1038/s41467-023-36185-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Accepted: 01/19/2023] [Indexed: 02/08/2023] Open
Abstract
Polyglutamine expansion in the androgen receptor (AR) causes spinobulbar muscular atrophy (SBMA). Skeletal muscle is a primary site of toxicity; however, the current understanding of the early pathological processes that occur and how they unfold during disease progression remains limited. Using transgenic and knock-in mice and patient-derived muscle biopsies, we show that SBMA mice in the presymptomatic stage develop a respiratory defect matching defective expression of genes involved in excitation-contraction coupling (ECC), altered contraction dynamics, and increased fatigue. These processes are followed by stimulus-dependent accumulation of calcium into mitochondria and structural disorganization of the muscle triads. Deregulation of expression of ECC genes is concomitant with sexual maturity and androgen raise in the serum. Consistent with the androgen-dependent nature of these alterations, surgical castration and AR silencing alleviate the early and late pathological processes. These observations show that ECC deregulation and defective mitochondrial respiration are early but reversible events followed by altered muscle force, calcium dyshomeostasis, and dismantling of triad structure.
Collapse
Affiliation(s)
- Caterina Marchioretti
- Department of Biomedical Sciences (DBS), University of Padova, 35131, Padova, Italy
- Veneto Institute of Molecular Medicine (VIMM), Padova, 35100, Italy
- Padova Neuroscience Center (PNC), Padova, 35100, Italy
- Dulbecco Telethon Institute (DTI) at the Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, 38123, Trento, Italy
| | - Giulia Zanetti
- Department of Biomedical Sciences (DBS), University of Padova, 35131, Padova, Italy
| | - Marco Pirazzini
- Department of Biomedical Sciences (DBS), University of Padova, 35131, Padova, Italy
- CIR-Myo, Centro Interdipartimentale di Ricerca di Miologia, University of Padova, 35131, Padova, Italy
| | - Gaia Gherardi
- Department of Biomedical Sciences (DBS), University of Padova, 35131, Padova, Italy
| | - Leonardo Nogara
- Department of Biomedical Sciences (DBS), University of Padova, 35131, Padova, Italy
- Veneto Institute of Molecular Medicine (VIMM), Padova, 35100, Italy
| | - Roberta Andreotti
- Department of Biomedical Sciences (DBS), University of Padova, 35131, Padova, Italy
- Veneto Institute of Molecular Medicine (VIMM), Padova, 35100, Italy
- Padova Neuroscience Center (PNC), Padova, 35100, Italy
| | - Paolo Martini
- Department of Molecular and Translational Medicine, University of Brescia, 25121, Brescia, Italy
| | - Lorenzo Marcucci
- Department of Biomedical Sciences (DBS), University of Padova, 35131, Padova, Italy
| | - Marta Canato
- Department of Biomedical Sciences (DBS), University of Padova, 35131, Padova, Italy
| | - Samir R Nath
- Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Emanuela Zuccaro
- Department of Biomedical Sciences (DBS), University of Padova, 35131, Padova, Italy
- Veneto Institute of Molecular Medicine (VIMM), Padova, 35100, Italy
- Padova Neuroscience Center (PNC), Padova, 35100, Italy
| | - Mathilde Chivet
- Dulbecco Telethon Institute (DTI) at the Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, 38123, Trento, Italy
| | - Cristina Mammucari
- Department of Biomedical Sciences (DBS), University of Padova, 35131, Padova, Italy
- CIR-Myo, Centro Interdipartimentale di Ricerca di Miologia, University of Padova, 35131, Padova, Italy
| | - Marco Pacifici
- Department of Biomedical Sciences (DBS), University of Padova, 35131, Padova, Italy
| | - Anna Raffaello
- Department of Biomedical Sciences (DBS), University of Padova, 35131, Padova, Italy
- CIR-Myo, Centro Interdipartimentale di Ricerca di Miologia, University of Padova, 35131, Padova, Italy
| | - Rosario Rizzuto
- Department of Biomedical Sciences (DBS), University of Padova, 35131, Padova, Italy
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131, Padova, Italy
| | - Maria A Desbats
- Clinical Genetics Unit, Department of Women and Children's Health, University of Padova, and Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy
| | - Leonardo Salviati
- CIR-Myo, Centro Interdipartimentale di Ricerca di Miologia, University of Padova, 35131, Padova, Italy
- Clinical Genetics Unit, Department of Women and Children's Health, University of Padova, and Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy
| | - Aram Megighian
- Department of Biomedical Sciences (DBS), University of Padova, 35131, Padova, Italy
- Padova Neuroscience Center (PNC), Padova, 35100, Italy
| | - Gianni Sorarù
- Padova Neuroscience Center (PNC), Padova, 35100, Italy
- Department of Neuroscience (DNS), University of Padova, 35128, Padova, Italy
| | - Elena Pegoraro
- Department of Neuroscience (DNS), University of Padova, 35128, Padova, Italy
| | - Elisa Belluzzi
- Orthopedics and Orthopedic Oncology, Department of Surgery, Oncology, and Gastroenterology DiSCOG, University-Hospital of Padova, 35128, Padova, Italy
- Musculoskeletal Pathology and Oncology Laboratory, Department of Surgery, Oncology and Gastroenterology (DiSCOG), University of Padova, 35128, Padova, Italy
| | - Assunta Pozzuoli
- Orthopedics and Orthopedic Oncology, Department of Surgery, Oncology, and Gastroenterology DiSCOG, University-Hospital of Padova, 35128, Padova, Italy
- Musculoskeletal Pathology and Oncology Laboratory, Department of Surgery, Oncology and Gastroenterology (DiSCOG), University of Padova, 35128, Padova, Italy
| | - Carlo Biz
- Orthopedics and Orthopedic Oncology, Department of Surgery, Oncology, and Gastroenterology DiSCOG, University-Hospital of Padova, 35128, Padova, Italy
| | - Pietro Ruggieri
- Orthopedics and Orthopedic Oncology, Department of Surgery, Oncology, and Gastroenterology DiSCOG, University-Hospital of Padova, 35128, Padova, Italy
| | - Chiara Romualdi
- Department of Biology, University of Padova, Padova, 35100, Italy
| | - Andrew P Lieberman
- Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Gopal J Babu
- Department of Cell Biology and Molecular Medicine, Rutgers, New Jersey Medical School, Newark, NJ, 07103, USA
| | - Marco Sandri
- Department of Biomedical Sciences (DBS), University of Padova, 35131, Padova, Italy
- Veneto Institute of Molecular Medicine (VIMM), Padova, 35100, Italy
| | - Bert Blaauw
- Department of Biomedical Sciences (DBS), University of Padova, 35131, Padova, Italy
- Veneto Institute of Molecular Medicine (VIMM), Padova, 35100, Italy
| | - Manuela Basso
- Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, 38123, Trento, Italy
| | - Maria Pennuto
- Department of Biomedical Sciences (DBS), University of Padova, 35131, Padova, Italy.
- Veneto Institute of Molecular Medicine (VIMM), Padova, 35100, Italy.
- Padova Neuroscience Center (PNC), Padova, 35100, Italy.
- Dulbecco Telethon Institute (DTI) at the Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, 38123, Trento, Italy.
| |
Collapse
|
9
|
Bettini E, Stahl SM, De Martin S, Mattarei A, Sgrignani J, Carignani C, Nola S, Locatelli P, Pappagallo M, Inturrisi CE, Bifari F, Cavalli A, Alimonti A, Pani L, Fava M, Traversa S, Folli F, Manfredi PL. Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors. Pharmaceuticals (Basel) 2022; 15:ph15080997. [PMID: 36015145 PMCID: PMC9414551 DOI: 10.3390/ph15080997] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2022] [Revised: 08/05/2022] [Accepted: 08/09/2022] [Indexed: 12/19/2022] Open
Abstract
Excessive Ca2+ currents via N-methyl-D-aspartate receptors (NMDARs) have been implicated in many disorders. Uncompetitive NMDAR channel blockers are an emerging class of drugs in clinical use for major depressive disorder (MDD) and other neuropsychiatric diseases. The pharmacological characterization of uncompetitive NMDAR blockers in clinical use may improve our understanding of NMDAR function in physiology and pathology. REL-1017 (esmethadone-HCl), a novel uncompetitive NMDAR channel blocker in Phase 3 trials for the treatment of MDD, was characterized together with dextromethorphan, memantine, (±)-ketamine, and MK-801 in cell lines over-expressing NMDAR subtypes using fluorometric imaging plate reader (FLIPR), automated patch-clamp, and manual patch-clamp electrophysiology. In the absence of Mg2+, NMDAR subtypes NR1-2D were most sensitive to low, sub-μM glutamate concentrations in FLIPR experiments. FLIPR Ca2+ determination demonstrated low μM affinity of REL-1017 at NMDARs with minimal subtype preference. In automated and manual patch-clamp electrophysiological experiments, REL-1017 exhibited preference for the NR1-2D NMDAR subtype in the presence of 1 mM Mg2+ and 1 μM L-glutamate. Tau off and trapping characteristics were similar for (±)-ketamine and REL-1017. Results of radioligand binding assays in rat cortical neurons correlated with the estimated affinities obtained in FLIPR assays and in automated and manual patch-clamp assays. In silico studies of NMDARs in closed and open conformation indicate that REL-1017 has a higher preference for docking and undocking the open-channel conformation compared to ketamine. In conclusion, the pharmacological characteristics of REL-1017 at NMDARs, including relatively low affinity at the NMDAR, NR1-2D subtype preference in the presence of 1 mM Mg2+, tau off and degree of trapping similar to (±)-ketamine, and preferential docking and undocking of the open NMDAR, could all be important variables for understanding the rapid-onset antidepressant effects of REL-1017 without psychotomimetic side effects.
Collapse
Affiliation(s)
- Ezio Bettini
- In Vitro Pharmacology Department, Aptuit, An Evotec Company, 37135 Verona, Italy
| | - Stephen M. Stahl
- Department of Psychiatry, VAMC (SD), University of California, San Diego, CA 92093, USA
- Neuroscience Education Institute, Carlsbad, CA 92008, USA
| | - Sara De Martin
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, 35122 Padua, Italy
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, 35122 Padua, Italy
| | - Jacopo Sgrignani
- Institute for Research in Biomedicine (IRB), Università della Svizzera Italiana (USI), 6500 Bellinzona, Switzerland
| | - Corrado Carignani
- In Vitro Pharmacology Department, Aptuit, An Evotec Company, 37135 Verona, Italy
| | - Selena Nola
- In Vitro Pharmacology Department, Aptuit, An Evotec Company, 37135 Verona, Italy
| | - Patrizia Locatelli
- Institute for Research in Biomedicine (IRB), Università della Svizzera Italiana (USI), 6500 Bellinzona, Switzerland
| | - Marco Pappagallo
- Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
- Relmada Therapeutics, Coral Gables, FL 33134, USA
| | | | - Francesco Bifari
- Department of Medical Biotechnology and Translational Medicine, University of Milan, 20122 Milan, Italy
| | - Andrea Cavalli
- Institute for Research in Biomedicine (IRB), Università della Svizzera Italiana (USI), 6500 Bellinzona, Switzerland
- Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland
| | - Andrea Alimonti
- Department of Health Sciences and Technology, ETH Zurich, 8092 Zurich, Switzerland
- Institute of Oncology Research, Southern Switzerland, 6500 Bellinzona, Switzerland
- The Institute of Oncology Research, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland
- Veneto Institute of Molecular Medicine, 35129 Padua, Italy
- Department of Medicine, Zurich University, 8006 Zurich, Switzerland
- Department of Medicine—DIMED, University of Padua, 35122 Padua, Italy
| | - Luca Pani
- Relmada Therapeutics, Coral Gables, FL 33134, USA
- Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Miami, Miami, FL 33136, USA
- Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy
| | - Maurizio Fava
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
| | | | - Franco Folli
- Department of Health Sciences, University of Milan, 20122 Milan, Italy
| | - Paolo L. Manfredi
- Relmada Therapeutics, Coral Gables, FL 33134, USA
- Correspondence: ; Tel.: +1-786-629-1376
| |
Collapse
|
10
|
Severin F, Urbani A, Varanita T, Bachmann M, Azzolini M, Martini V, Pizzi M, Tos APD, Frezzato F, Mattarei A, Ghia P, Bertilaccio MTS, Gulbins E, Paradisi C, Zoratti M, Semenzato GC, Leanza L, Trentin L, Szabò I. Pharmacological modulation of Kv1.3 potassium channel selectively triggers pathological B lymphocyte apoptosis in vivo in a genetic CLL model. J Exp Clin Cancer Res 2022; 41:64. [PMID: 35172855 PMCID: PMC8848658 DOI: 10.1186/s13046-022-02249-w] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2021] [Accepted: 01/07/2022] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Ion channels are emerging as promising oncological targets. The potassium channels Kv1.3 and IKCa are highly expressed in the plasma membrane and mitochondria of human chronic lymphocytic leukemia (CLL) cells, compared to healthy lymphocytes. In vitro, inhibition of mitoKv1.3 by PAPTP was shown to kill ex vivo primary human CLL cells, while targeting IKCa with TRAM-34 decreased CLL cell proliferation. METHODS Here we evaluated the effect of the above drugs in CLL cells from ibrutinib-resistant patients and in combination with Venetoclax, two drugs used in the clinical practice. The effects of the drugs were tested also in the Eμ-TCL1 genetic CLL murine model, characterized by a lympho-proliferative disease reminiscent of aggressive human CLL. Eμ-TCL1 mice showing overt disease state were treated with intraperitoneal injections of non-toxic 5 nmol/g PAPTP or 10 nmol/g TRAM-34 once a day and the number and percentage of pathological B cells (CD19+CD5+) in different, pathologically relevant body districts were determined. RESULTS We show that Kv1.3 expression correlates with sensitivity of the human and mouse neoplastic cells to PAPTP. Primary CLL cells from ibrutinib-resistant patients could be killed with PAPTP and this drug enhanced the effect of Venetoclax, by acting on mitoKv1.3 of the inner mitochondrial membrane and triggering rapid mitochondrial changes and cytochrome c release. In vivo, after 2 week- therapy of Eμ-TCL1 mice harboring distinct CLL clones, leukemia burden was reduced by more than 85%: the number and percentage of CLL B cells fall in the spleen and peritoneal cavity and in the peripheral blood, without signs of toxicity. Notably, CLL infiltration into liver and spleen and splenomegaly were also drastically reduced upon PAPTP treatment. In contrast, TRAM-34 did not exert any beneficial effect when administered in vivo to Eμ-TCL1 mice at non-toxic concentration. CONCLUSION Altogether, by comparing vehicle versus compound effect in different Eμ-TCL1 animals bearing unique clones similarly to CLL patients, we conclude that PAPTP significantly reduced leukemia burden in CLL-relevant districts, even in animals with advanced stage of the disease. Our results thus identify PAPTP as a very promising drug for CLL treatment, even for the chemoresistant forms of the disease.
Collapse
Affiliation(s)
- Filippo Severin
- Department of Medicine, Hematology and Clinical Immunology Branch, University of Padua School of Medicine, Padua, Italy and Veneto Institute of Molecular Medicine (VIMM), Padua, Italy
| | - Andrea Urbani
- Department of Biomedical Sciences, University of Padua, Padua, Italy.,Department of Biology, University of Padua, Padua, Italy
| | | | | | - Michele Azzolini
- Department of Biomedical Sciences, University of Padua, Padua, Italy
| | - Veronica Martini
- Department of Medicine, Hematology and Clinical Immunology Branch, University of Padua School of Medicine, Padua, Italy and Veneto Institute of Molecular Medicine (VIMM), Padua, Italy
| | - Marco Pizzi
- Department of Medicine, Pathology Branch, University of Padua School of Medicine, Padua, Italy
| | - Angelo Paolo Dei Tos
- Department of Medicine, Pathology Branch, University of Padua School of Medicine, Padua, Italy
| | - Federica Frezzato
- Department of Medicine, Hematology and Clinical Immunology Branch, University of Padua School of Medicine, Padua, Italy and Veneto Institute of Molecular Medicine (VIMM), Padua, Italy
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy
| | - Paolo Ghia
- Università Vita-Salute San Raffaele and IRCC Ospedale San Raffaele, Milan, Italy
| | | | - Erich Gulbins
- Department of Molecular Biology, University of Duisburg-Essen, Essen, Germany
| | | | - Mario Zoratti
- Department of Biomedical Sciences, University of Padua, Padua, Italy.,CNR Institute of Neurosciences, University of Padua, Padua, Italy
| | - Gianpietro Carlo Semenzato
- Department of Medicine, Hematology and Clinical Immunology Branch, University of Padua School of Medicine, Padua, Italy and Veneto Institute of Molecular Medicine (VIMM), Padua, Italy
| | - Luigi Leanza
- Department of Biology, University of Padua, Padua, Italy.
| | - Livio Trentin
- Department of Medicine, Hematology and Clinical Immunology Branch, University of Padua School of Medicine, Padua, Italy and Veneto Institute of Molecular Medicine (VIMM), Padua, Italy.
| | - Ildiko Szabò
- Department of Biology, University of Padua, Padua, Italy. .,CNR Institute of Neurosciences, University of Padua, Padua, Italy.
| |
Collapse
|
11
|
Ongaro A, Violatto MB, Casarin E, Pellerani I, Marchini G, Ribaudo G, Salmona M, Carbone M, Passoni A, Gnodi E, Schiavon E, Mattarei A, Barisani D, Invernizzi P, Bigini P, Morpurgo M. The mode of dexamethasone decoration influences avidin-nucleic-acid-nano-assembly organ biodistribution and in vivo drug persistence. Nanomedicine 2022; 40:102497. [PMID: 34838993 DOI: 10.1016/j.nano.2021.102497] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 10/28/2021] [Accepted: 11/01/2021] [Indexed: 12/12/2022]
Abstract
Avidin-Nucleic-Acid-NanoASsemblies (ANANAS) possess natural tropism for the liver and, when loaded with dexamethasone, reduce clinical progression in an autoimmune hepatitis murine model. Here, we investigated the linker chemistry (hydrazide-hydrazone, Hz-Hz, or carbamate hydrazide-hydrazone, Cb-Hz bond) and length (long, 5 kDa PEG, or short, 5-6 carbons) in biotin-dexamethasone conjugates used for nanoparticle decoration through in vitro and in vivo studies. All four newly synthesized conjugates released the drug at acidic pH only. In vitro, the Hz-Hz and the PEG derivatives were less stable than the Cb-Hz and the short chain ones, respectively. Once injected in healthy mice, dexamethasone location in the PEGylated ANANAS outer layer favors liver penetration and resident macrophages uptake, while drug Hz-Hz, but not Cb-Hz, short spacing prolongs drug availability. In conclusion, the tight modulation of ANANAS decoration can significantly influence the host interaction, paving the way for the development of steroid nanoformulations suitable for different pharmacokinetic profiles.
Collapse
Affiliation(s)
- Alberto Ongaro
- Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Martina Bruna Violatto
- Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, Milano, Italy
| | | | - Isabella Pellerani
- Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, Milano, Italy
| | - Gloria Marchini
- Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, Milano, Italy
| | - Giovanni Ribaudo
- Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Mario Salmona
- Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, Milano, Italy
| | - Marco Carbone
- Division of Gastroenterology and Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital, Monza, Italy; International Center for Digestive Diseases
| | - Alice Passoni
- Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, Milano, Italy
| | - Elisa Gnodi
- Division of Gastroenterology and Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; International Center for Digestive Diseases
| | - Elisa Schiavon
- Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Andrea Mattarei
- Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Donatella Barisani
- Division of Gastroenterology and Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; International Center for Digestive Diseases
| | - Pietro Invernizzi
- Division of Gastroenterology and Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital, Monza, Italy; International Center for Digestive Diseases
| | - Paolo Bigini
- Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, Milano, Italy
| | - Margherita Morpurgo
- Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy; CRIBI Biotechnology Cente, University of Padova, Padova, Italy.
| |
Collapse
|
12
|
Fava M, Stahl S, Pani L, De Martin S, Pappagallo M, Guidetti C, Alimonti A, Bettini E, Mangano RM, Wessel T, de Somer M, Caron J, Vitolo OV, DiGuglielmo GR, Gilbert A, Mehta H, Kearney M, Mattarei A, Gentilucci M, Folli F, Traversa S, Inturrisi CE, Manfredi PL. REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial. Am J Psychiatry 2022; 179:122-131. [PMID: 34933568 DOI: 10.1176/appi.ajp.2021.21020197] [Citation(s) in RCA: 38] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Objective: The purpose of this study was to examine the effects of REL-1017 (esmethadone), a novel N-methyl-d-aspartate receptor (NMDAR) channel blocker, in patients with major depressive disorder who failed to benefit from one to three standard antidepressant treatments in their current major depressive episode. Methods: A 7-day phase 2 multicenter randomized double-blind placebo-controlled trial, comprising three arms, was conducted to assess the safety, tolerability, pharmacokinetics, and efficacy of two dosages of REL-1017 (25 mg or 50 mg orally once a day). Patients were randomly assigned in a 1:1:1 ratio to placebo (N=22), REL-1017 25 mg/day (N=19), or REL-1017 50 mg/day (N=21). Safety scales included the 4-item Positive Symptom Rating Scale for psychotomimetic symptoms, the Clinician-Administered Dissociative States Scale for dissociative symptoms, the Clinical Opiate Withdrawal Scale for withdrawal signs and symptoms, and the Columbia-Suicide Severity Rating Scale for suicidality. The primary efficacy endpoint was the Montgomery-Åsberg Depression Scale (MADRS) score. All 62 randomly assigned patients were included in the full analysis set population analysis. Results: Patients experienced mild or moderate transient adverse events and no evidence of dissociative or psychotomimetic effects, opioid effects, or withdrawal signs and symptoms. The improvement in MADRS score shown on day 4 in both of the REL-1017 dosage groups was sustained through day 7 (last dose) and day 14 (7 days after the last dose), with effect sizes from 0.7 to 1.0. Conclusions: This trial showed favorable safety, tolerability, and pharmacokinetic profiles and suggests that REL-1017 may have rapid and sustained antidepressant effects compared with placebo in patients with inadequate responses to antidepressant treatments. These results will need confirmation in larger and longer trials.
Collapse
Affiliation(s)
- Maurizio Fava
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Stephen Stahl
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Luca Pani
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Sara De Martin
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Marco Pappagallo
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Clotilde Guidetti
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Andrea Alimonti
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Ezio Bettini
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Richard M Mangano
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Thomas Wessel
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Marc de Somer
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Judy Caron
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Ottavio V Vitolo
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Gina R DiGuglielmo
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Adam Gilbert
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Hiren Mehta
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Morgan Kearney
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Andrea Mattarei
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Marco Gentilucci
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Franco Folli
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Sergio Traversa
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Charles E Inturrisi
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| | - Paolo L Manfredi
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy (Guidetti); Catholic University of the Sacred Heart, Rome (Guidetti); Department of Neuroscience, Child and Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome (Guidetti); Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland (Alimonti); Institute of Oncology Research, Southern Switzerland, Bellinzona (Alimonti); Università della Svizzera Italiana, Bellinzona (Alimonti); Veneto Institute of Molecular Medicine, Padua, Italy (Alimonti); Department of Medicine, Zurich University, Zurich (Alimonti); University of Padua, Padua, Italy (Alimonti); In Vitro Pharmacology Department, Aptuit an Evotec Company, Verona, Italy (Bettini); Drexel University College of Medicine, Philadelphia (Mangano); Relmada Therapeutics, New York (Pappagallo, Wessel, de Somer, Caron, DiGuglielmo, Traversa, Inturrisi, Manfredi); Department of Cardiology, Syneos Health, Morrisville, N.C. (Gilbert, Mehta, Kearney); Department of Medicine, Albert Einstein College of Medicine, Bronx, N.Y. (Gentilucci); and Department of Health Science, University of Milan, Milan, Italy (Folli)
| |
Collapse
|
13
|
Stazi M, Fabris F, Tan KY, Megighian A, Rubini A, Mattarei A, Negro S, D'Este G, Lista F, Rossetto O, Tan CH, Montecucco C. An agonist of the CXCR4 receptor is therapeutic for the neuroparalysis induced by
Bungarus
snakes envenoming. Clin Transl Med 2022; 12:e651. [PMID: 35075797 PMCID: PMC8787102 DOI: 10.1002/ctm2.651] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2021] [Revised: 10/27/2021] [Accepted: 10/31/2021] [Indexed: 11/08/2022] Open
Affiliation(s)
- Marco Stazi
- Department of Biomedical Sciences University of Padova Padova Italy
| | - Federico Fabris
- Department of Biomedical Sciences University of Padova Padova Italy
| | - Kae Yi Tan
- Department of Molecular Medicine Faculty of Medicine University of Malaya Kuala Lumpur Malaysia
| | - Aram Megighian
- Department of Biomedical Sciences University of Padova Padova Italy
| | | | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences University of Padova Padova Italy
| | - Samuele Negro
- Department of Biomedical Sciences University of Padova Padova Italy
| | - Giorgia D'Este
- Department of Biomedical Sciences University of Padova Padova Italy
| | - Florigio Lista
- Center of Medical and Veterinary Research of the Ministry of Defense Policlinico Militare Rome Italy
| | - Ornella Rossetto
- Department of Biomedical Sciences University of Padova Padova Italy
| | - Choo Hock Tan
- Department of Pharmacology Faculty of Medicine University of Malaya Kuala Lumpur Malaysia
| | - Cesare Montecucco
- Department of Biomedical Sciences University of Padova Padova Italy
- CNR Institute of Neuroscience Padova Italy
| |
Collapse
|
14
|
Romio M, Grob B, Trachsel L, Mattarei A, Morgese G, Ramakrishna SN, Niccolai F, Guazzelli E, Paradisi C, Martinelli E, Spencer ND, Benetti EM. Dispersity within Brushes Plays a Major Role in Determining Their Interfacial Properties: The Case of Oligoxazoline-Based Graft Polymers. J Am Chem Soc 2021; 143:19067-19077. [PMID: 34738797 PMCID: PMC8769490 DOI: 10.1021/jacs.1c08383] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2021] [Indexed: 12/14/2022]
Abstract
Many synthetic polymers used to form polymer-brush films feature a main backbone with functional, oligomeric side chains. While the structure of such graft polymers mimics biomacromolecules to an extent, it lacks the monodispersity and structural purity present in nature. Here we demonstrate that side-chain heterogeneity within graft polymers significantly influences hydration and the occurrence of hydrophobic interactions in the subsequently formed brushes and consequently impacts fundamental interfacial properties. This is demonstrated for the case of poly(methacrylate)s (PMAs) presenting oligomeric side chains of different length (n) and dispersity. A precise tuning of brush structure was achieved by first synthesizing oligo(2-ethyl-2-oxazoline) methacrylates (OEOXMAs) by cationic ring-opening polymerization (CROP), subsequently purifying them into discrete macromonomers with distinct values of n by column chromatography, and finally obtaining poly[oligo(2-ethyl-2-oxazoline) methacrylate]s (POEOXMAs) by reversible addition-fragmentation chain-transfer (RAFT) polymerization. Assembly of POEOXMA on Au surfaces yielded graft polymer brushes with different side-chain dispersities and lengths, whose properties were thoroughly investigated by a combination of variable angle spectroscopic ellipsometry (VASE), quartz crystal microbalance with dissipation (QCMD), and atomic force microscopy (AFM) methods. Side-chain dispersity, or dispersity within brushes, leads to assemblies that are more hydrated, less adhesive, and more lubricious and biopassive compared to analogous films obtained from graft polymers characterized by a homogeneous structure.
Collapse
Affiliation(s)
- Matteo Romio
- Biointerfaces
Lab, Swiss Federal Laboratories for Materials
Science and Technology (Empa), Lerchenfeldstrasse 5, 9014 St. Gallen, Switzerland
- Laboratory
for Surface Science and Technology, Department of Materials, ETH Zürich, Vladimir-Prelog-Weg 5, 8093 Zürich, Switzerland
| | - Benjamin Grob
- Laboratory
for Surface Science and Technology, Department of Materials, ETH Zürich, Vladimir-Prelog-Weg 5, 8093 Zürich, Switzerland
| | - Lucca Trachsel
- George
& Josephine Butler Polymer Research Laboratory, Department of
Chemistry, University of Florida, P.O. Box 117200, Gainesville, Florida 32611-7200, United States
| | - Andrea Mattarei
- Department
of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy
| | - Giulia Morgese
- Institute
of Materials and Process Engineering (IMPE), School of Engineering
(SoE), Zürich University of Applied
Sciences (ZHAW), Technikumstrasse 9, 8401 Winterthur, Switzerland
| | - Shivaprakash N. Ramakrishna
- Soft Materials
and Interfaces, Department of Materials, ETH Zürich, Vladimir-Prelog-Weg
5, 8093 Zürich, Switzerland
| | - Francesca Niccolai
- Department
of Chemistry and Industrial Chemistry, University
of Pisa, Via Moruzzi 13, 56124 Pisa, Italy
| | - Elisa Guazzelli
- Department
of Chemistry and Industrial Chemistry, University
of Pisa, Via Moruzzi 13, 56124 Pisa, Italy
| | - Cristina Paradisi
- Department
of Chemical Sciences, University of Padova, Via Marzolo 1, 35122 Padova, Italy
| | - Elisa Martinelli
- Department
of Chemistry and Industrial Chemistry, University
of Pisa, Via Moruzzi 13, 56124 Pisa, Italy
| | - Nicholas D. Spencer
- Laboratory
for Surface Science and Technology, Department of Materials, ETH Zürich, Vladimir-Prelog-Weg 5, 8093 Zürich, Switzerland
| | - Edmondo M. Benetti
- Biointerfaces
Lab, Swiss Federal Laboratories for Materials
Science and Technology (Empa), Lerchenfeldstrasse 5, 9014 St. Gallen, Switzerland
- Laboratory
for Surface Science and Technology, Department of Materials, ETH Zürich, Vladimir-Prelog-Weg 5, 8093 Zürich, Switzerland
- Department
of Chemical Sciences, University of Padova, Via Marzolo 1, 35122 Padova, Italy
| |
Collapse
|
15
|
Zanetti G, Mattarei A, Lista F, Rossetto O, Montecucco C, Pirazzini M. Novel Small Molecule Inhibitors That Prevent the Neuroparalysis of Tetanus Neurotoxin. Pharmaceuticals (Basel) 2021; 14:ph14111134. [PMID: 34832916 PMCID: PMC8618345 DOI: 10.3390/ph14111134] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2021] [Revised: 10/25/2021] [Accepted: 11/04/2021] [Indexed: 01/22/2023] Open
Abstract
Tetanus neurotoxin (TeNT) is a protein exotoxin produced by Clostridium tetani that causes the deadly spastic neuroparalysis of tetanus. It consists of a metalloprotease light chain and of a heavy chain linked via a disulphide bond. TeNT binds to the neuromuscular junction (NMJ) and it is retro-axonally transported into vesicular compartments to the spinal cord, where it is released and taken up by inhibitory interneuron. Therein, the catalytic subunit is translocated into the cytoplasm where it cleaves its target protein VAMP-1/2 with consequent blockage of the release of inhibitory neurotransmitters. Vaccination with formaldehyde inactivated TeNT prevents the disease, but tetanus is still present in countries where vaccination coverage is partial. Here, we show that small molecule inhibitors interfering with TeNT trafficking or with the reduction of the interchain disulphide bond block the activity of the toxin in neuronal cultures and attenuate tetanus symptoms in vivo. These findings are relevant for the development of therapeutics against tetanus based on the inhibition of toxin molecules that are being retro-transported to or are already within the spinal cord and are, thus, not accessible to anti-TeNT immunoglobulins.
Collapse
Affiliation(s)
- Giulia Zanetti
- Department of Biomedical Sciences, University of Padova, Via U. Bassi 58/B, 35121 Padova, Italy; (G.Z.); (O.R.)
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via F. Marzolo 5, 35131 Padova, Italy;
| | - Florigio Lista
- Scientific Department, Army Medical Center, Via Santo Stefano Rotondo 4, 00184 Rome, Italy;
| | - Ornella Rossetto
- Department of Biomedical Sciences, University of Padova, Via U. Bassi 58/B, 35121 Padova, Italy; (G.Z.); (O.R.)
- Italian Research Council, Institute of Neuroscience, University of Padova, Via U. Bassi 58/B, 35121 Padova, Italy
- CIR-Myo, Centro Interdipartimentale di Ricerca di Miologia, University of Padova, Via U. Bassi 58/B, 35131 Padova, Italy
| | - Cesare Montecucco
- Department of Biomedical Sciences, University of Padova, Via U. Bassi 58/B, 35121 Padova, Italy; (G.Z.); (O.R.)
- Italian Research Council, Institute of Neuroscience, University of Padova, Via U. Bassi 58/B, 35121 Padova, Italy
- Correspondence: (C.M.); (M.P.)
| | - Marco Pirazzini
- Department of Biomedical Sciences, University of Padova, Via U. Bassi 58/B, 35121 Padova, Italy; (G.Z.); (O.R.)
- CIR-Myo, Centro Interdipartimentale di Ricerca di Miologia, University of Padova, Via U. Bassi 58/B, 35131 Padova, Italy
- Correspondence: (C.M.); (M.P.)
| |
Collapse
|
16
|
Biasutto L, Mattarei A, Paradisi C. Synthesis and Testing of Novel Isomeric Mitochondriotropic Derivatives of Resveratrol and Quercetin. Methods Mol Biol 2021; 2275:141-160. [PMID: 34118036 DOI: 10.1007/978-1-0716-1262-0_9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Resveratrol and quercetin are among the most studied plant polyphenols, and have many health-promoting actions. Strategies to accumulate them into mitochondria may be of therapeutic relevance, since these compounds are redox active and are well known to impact mitochondria and mitochondrial proteins. We report here the procedures to synthesize mitochondria-targeted resveratrol and quercetin derivatives; the synthetic strategies reported are however expected to be adaptable to other polyphenols with similar reactivity at the phenolic hydroxyls. Mitochondrial targeting can be achieved by conjugation with triphenylphosphonium , a lipophilic cation; this was linked via a butyl spacer forming an ether bond with one of the phenolic oxygens. The first step toward the synthesis of all mitochondriotropic derivatives described in this work is the production of a regiospecific -(4-O-chlorobutyl) derivative. Triphenylphosphonium (P+Ph3I-) is then introduced through two consecutive nucleophilic substitution steps: -Cl → -I → -P+Ph3I-. Pure mono-substituted chlorobutyl regioisomers are obtained by purification from the reaction mixture in the case of resveratrol , while specific protection strategies are required for quercetin to favor alkylation of one specific hydroxyl.Functionalization of the remaining hydroxyls can be exploited to modulate the physicochemical properties of the derivatives (i.e., water solubility, affinity for cell membranes); we report here synthetic protocols to obtain acetylated and methylated analogs.A brief description of some methods to assess the accumulation of the derivatives in mitochondria is also given; the proposed techniques are the use of a TPP +-selective electrode (with isolated rat liver mitochondria ) and fluorescence microscopy (with cultured cells).
Collapse
Affiliation(s)
- Lucia Biasutto
- CNR Institute of Neurosciences, Padova, Italy. .,Department of Biomedical Sciences, University of Padova, Padova, Italy.
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Cristina Paradisi
- Department of Chemical Sciences, University of Padova, Padova, Italy
| |
Collapse
|
17
|
De Nadai A, Vajente N, Pendin D, Mattarei A. Mt-fura-2, a Ratiometric Mitochondria-Targeted Ca 2+ Sensor. Determination of Spectroscopic Properties and Ca 2+ Imaging Assays. Methods Mol Biol 2021; 2275:187-215. [PMID: 34118039 DOI: 10.1007/978-1-0716-1262-0_12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
Ca2+ handling by mitochondria is implicated in energy production, shaping of cytosolic Ca2+ rises, and determination of cell fate. It is therefore of crucial interest for researchers to directly measure mitochondrial Ca2+ concentration [Ca2+] in living cells. Synthetic fluorescent Ca2+ indicators, providing a straightforward loading technique, represents a tempting strategy. Recently, we developed a new highly selective mitochondria-targeted Ca2+ indicator named mt-fura-2 , obtained by coupling two triphenylphosphonium cation-containing groups to the molecular backbone of the cytosolic ratiometric Ca2+ indicator fura-2 .The protocols we describe here cover all the significant steps that are necessary to characterize the probe and apply it to biologically relevant contexts. The procedures reported are referred to mt-fura-2 but could in principle be applied to characterize other mitochondria-targeted Ca2+ probes . More in general, with the due modifications, this chapter can be considered as a handbook for the characterization and/or application of mitochondria-targeted chemical Ca2+ probes .
Collapse
Affiliation(s)
- Andrea De Nadai
- Department of Chemical Sciences, University of Padua, Padua, Italy
| | - Nicola Vajente
- Neuroscience Institute, Padua Section, National Research Council, Padua, Italy
| | - Diana Pendin
- Neuroscience Institute, Padua Section, National Research Council, Padua, Italy
- Department of Biomedical Sciences, University of Padua, Padua, Italy
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
| |
Collapse
|
18
|
Peruzzo R, Mattarei A, Azzolini M, Becker-Flegler KA, Romio M, Rigoni G, Carrer A, Biasutto L, Parrasia S, Kadow S, Managò A, Urbani A, Rossa A, Semenzato G, Soriano ME, Trentin L, Ahmad S, Edwards M, Gulbins E, Paradisi C, Zoratti M, Leanza L, Szabò I. Corrigendum to "Insight into the mechanism of cytotoxicity of membrane-permeant psoralenic Kv1.3 channel inhibitors by chemical dissection of a novel member of the family" [Redox Biol. 37 (2020 Sep 6) 101705-101721]. Redox Biol 2021; 45:102036. [PMID: 34210643 PMCID: PMC8270548 DOI: 10.1016/j.redox.2021.102036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Affiliation(s)
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Italy
| | | | | | - Matteo Romio
- Department of Chemical Sciences, University of Padua, Italy
| | | | - Andrea Carrer
- Department of Biology, University of Padua, Italy; Department of Biomedical Sciences, University of Padua, Italy
| | - Lucia Biasutto
- Department of Biomedical Sciences, University of Padua, Italy; CNR Institute of Neuroscience, Padua, Italy
| | - Sofia Parrasia
- Department of Biomedical Sciences, University of Padua, Italy
| | - Stephanie Kadow
- Department of Molecular Biology, University of Duisburg-Essen, Germany
| | | | - Andrea Urbani
- Department of Biology, University of Padua, Italy; Department of Biomedical Sciences, University of Padua, Italy
| | - Andrea Rossa
- Department of Chemical Sciences, University of Padua, Italy
| | | | | | | | - Syed Ahmad
- Department of Surgery, Medical School, University of Cincinnati, USA
| | - Michael Edwards
- Department of Surgery, Medical School, University of Cincinnati, USA
| | - Erich Gulbins
- Department of Molecular Biology, University of Duisburg-Essen, Germany
| | | | - Mario Zoratti
- Department of Biomedical Sciences, University of Padua, Italy; CNR Institute of Neuroscience, Padua, Italy
| | - Luigi Leanza
- Department of Biology, University of Padua, Italy
| | - Ildikò Szabò
- Department of Biology, University of Padua, Italy; CNR Institute of Neuroscience, Padua, Italy.
| |
Collapse
|
19
|
Parrasia S, Rossa A, Varanita T, Checchetto V, De Lorenzi R, Zoratti M, Paradisi C, Ruzza P, Mattarei A, Szabò I, Biasutto L. An Angiopep2-PAPTP Construct Overcomes the Blood-Brain Barrier. New Perspectives against Brain Tumors. Pharmaceuticals (Basel) 2021; 14:ph14020129. [PMID: 33562146 PMCID: PMC7914648 DOI: 10.3390/ph14020129] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Revised: 01/30/2021] [Accepted: 02/03/2021] [Indexed: 12/23/2022] Open
Abstract
A developing family of chemotherapeutics—derived from 5-(4-phenoxybutoxy)psoralen (PAP-1)—target mitochondrial potassium channel mtKv1.3 to selectively induce oxidative stress and death of diseased cells. The key to their effectiveness is the presence of a positively charged triphenylphosphonium group which drives their accumulation in the organelles. These compounds have proven their preclinical worth in murine models of cancers such as melanoma and pancreatic adenocarcinoma. In in vitro experiments they also efficiently killed glioblastoma cells, but in vivo they were powerless against orthotopic glioma because they were completely unable to overcome the blood-brain barrier. In an effort to improve brain delivery we have now coupled one of these promising compounds, PAPTP, to well-known cell-penetrating and brain-targeting peptides TAT48–61 and Angiopep-2. Coupling has been obtained by linking one of the phenyl groups of the triphenylphosphonium to the first amino acid of the peptide via a reversible carbamate ester bond. Both TAT48–61 and Angiopep-2 allowed the delivery of 0.3–0.4 nmoles of construct per gram of brain tissue upon intravenous (i.v.) injection of 5 µmoles/kg bw to mice. This is the first evidence of PAPTP delivery to the brain; the chemical strategy described here opens the possibility to conjugate PAPTP to small peptides in order to fine-tune tissue distribution of this interesting compound.
Collapse
Affiliation(s)
- Sofia Parrasia
- Department of Biomedical Sciences, University of Padova, Viale G. Colombo 3, 35131 Padova, Italy; (S.P.); (M.Z.)
| | - Andrea Rossa
- Department of Chemical Sciences, University of Padova, Via F. Marzolo 1, 35131 Padova, Italy; (A.R.); (R.D.L.); (C.P.); (P.R.)
| | - Tatiana Varanita
- Department of Biology, University of Padova, Viale G. Colombo 3, 35131 Padova, Italy; (T.V.); (V.C.); (I.S.)
| | - Vanessa Checchetto
- Department of Biology, University of Padova, Viale G. Colombo 3, 35131 Padova, Italy; (T.V.); (V.C.); (I.S.)
| | - Riccardo De Lorenzi
- Department of Chemical Sciences, University of Padova, Via F. Marzolo 1, 35131 Padova, Italy; (A.R.); (R.D.L.); (C.P.); (P.R.)
- CNR Institute of Biomolecular Chemistry, Via F. Marzolo 1, 35131 Padova, Italy
| | - Mario Zoratti
- Department of Biomedical Sciences, University of Padova, Viale G. Colombo 3, 35131 Padova, Italy; (S.P.); (M.Z.)
- CNR Neuroscience Institute, Viale G. Colombo 3, 35131 Padova, Italy
| | - Cristina Paradisi
- Department of Chemical Sciences, University of Padova, Via F. Marzolo 1, 35131 Padova, Italy; (A.R.); (R.D.L.); (C.P.); (P.R.)
| | - Paolo Ruzza
- Department of Chemical Sciences, University of Padova, Via F. Marzolo 1, 35131 Padova, Italy; (A.R.); (R.D.L.); (C.P.); (P.R.)
- CNR Institute of Biomolecular Chemistry, Via F. Marzolo 1, 35131 Padova, Italy
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via F. Marzolo 5, 35131 Padova, Italy;
| | - Ildikò Szabò
- Department of Biology, University of Padova, Viale G. Colombo 3, 35131 Padova, Italy; (T.V.); (V.C.); (I.S.)
| | - Lucia Biasutto
- Department of Biomedical Sciences, University of Padova, Viale G. Colombo 3, 35131 Padova, Italy; (S.P.); (M.Z.)
- CNR Neuroscience Institute, Viale G. Colombo 3, 35131 Padova, Italy
- Correspondence:
| |
Collapse
|
20
|
Bachmann M, Rossa A, Antoniazzi G, Biasutto L, Carrer A, Campagnaro M, Leanza L, Gonczi M, Csernoch L, Paradisi C, Mattarei A, Zoratti M, Szabo I. Synthesis and cellular effects of a mitochondria-targeted inhibitor of the two-pore potassium channel TASK-3. Pharmacol Res 2021; 164:105326. [PMID: 33338625 DOI: 10.1016/j.phrs.2020.105326] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/08/2020] [Revised: 11/03/2020] [Accepted: 11/23/2020] [Indexed: 01/25/2023]
Abstract
The two-pore potassium channel TASK-3 has been shown to localize to both the plasma membrane and the mitochondrial inner membrane. TASK-3 is highly expressed in melanoma and breast cancer cells and has been proposed to promote tumor formation. Here we investigated whether pharmacological modulation of TASK-3, and specifically of mitochondrial TASK-3 (mitoTASK-3), had any effect on cancer cell survival and mitochondrial physiology. A novel, mitochondriotropic version of the specific TASK-3 inhibitor IN-THPP has been synthesized by addition of a positively charged triphenylphosphonium moiety. While IN-THPP was unable to induce apoptosis, mitoIN-THPP decreased survival of breast cancer cells and efficiently killed melanoma lines, which we show to express mitoTASK-3. Cell death was accompanied by mitochondrial membrane depolarization and fragmentation of the mitochondrial network, suggesting a role of the channel in the maintenance of the correct function of this organelle. In accordance, cells treated with mitoIN-THPP became rapidly depleted of mitochondrial ATP which resulted in activation of the AMP-dependent kinase AMPK. Importantly, cell survival was not affected in mouse embryonic fibroblasts and the effect of mitoIN-THPP was less pronounced in human melanoma cells stably knocked down for TASK-3 expression, indicating a certain degree of selectivity of the drug both for pathological cells and for the channel. In addition, mitoIN-THPP inhibited cancer cell migration to a higher extent than IN-THPP in two melanoma cell lines. In summary, our results point to the importance of mitoTASK-3 for melanoma cell survival and migration.
Collapse
Affiliation(s)
| | - Andrea Rossa
- Department of Chemical Sciences, University of Padua, Italy
| | | | - Lucia Biasutto
- CNR Institute of Neuroscience, Padua, Italy; Department of Biomedical Sciences, University of Padua, Italy
| | - Andrea Carrer
- Department of Biology, University of Padua, Italy; Department of Biomedical Sciences, University of Padua, Italy
| | | | - Luigi Leanza
- Department of Biology, University of Padua, Italy
| | - Monika Gonczi
- Department of Physiology, Faculty of Medicine, University of Debrecen, Hungary
| | - Laszlo Csernoch
- Department of Physiology, Faculty of Medicine, University of Debrecen, Hungary
| | | | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Italy
| | - Mario Zoratti
- CNR Institute of Neuroscience, Padua, Italy; Department of Biomedical Sciences, University of Padua, Italy
| | - Ildiko Szabo
- Department of Biology, University of Padua, Italy; CNR Institute of Neuroscience, Padua, Italy.
| |
Collapse
|
21
|
Popilski H, Feinshtein V, Kleiman S, Mattarei A, Garofalo M, Salmaso S, Stepensky D. Doxorubicin liposomes cell penetration enhancement and its potential drawbacks for the tumor targeting efficiency. Int J Pharm 2020; 592:120012. [PMID: 33152480 DOI: 10.1016/j.ijpharm.2020.120012] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2020] [Revised: 10/18/2020] [Accepted: 10/19/2020] [Indexed: 12/15/2022]
Abstract
The clinical efficacy of the PEGylated doxorubicin liposomes (PLD) is limited by low tumor accumulation and limited intra-tumoral disposition. Decoration with the cell penetration enhancers (CPEs) can increase the PLD permeability via the biological barriers, however at the expense of enhanced distribution to the non-target organs and tissues, and may interfere with their tumor accumulation and with the resulting anti-cancer effects. We investigated the effect of the surface CPE agent tetraArg-[G-1]-distearoyl glycerol (DAG-Arg4) on the systemic and intra-tumoral accumulation of PLD, using a 4 T1-Luc murine orthotopic model of breast cancer, using several analytical approaches. CPE-decorated liposomes undergo efficient in vitro endocytosis, and delivered doxorubicin to the cell nuclei. In vivo, they had lower tumor and spleen accumulation, similar liver accumulation, and higher lung accumulation, as compared to those of the PLD. Despite the lower tumor accumulation, CPE-decorated liposomes induced more prominent in vivo anti-cancer effects, as compared to the PLD, apparently ascribable to the higher intra-tumoral permeability mediated by the CPE surface residues. Overall, liposomes decoration with the CPE residues had mostly beneficial effects on their systemic and intra-tumoral disposition. The mechanisms of the CPE-mediated effects on the liposome disposition should be further assessed with additional experimental models using robust analytical methods with high spatial resolution.
Collapse
Affiliation(s)
- Hen Popilski
- Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
| | - Valeria Feinshtein
- Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
| | - Sivan Kleiman
- Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Mariangela Garofalo
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Stefano Salmaso
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - David Stepensky
- Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
| |
Collapse
|
22
|
Peruzzo R, Mattarei A, Azzolini M, Becker-Flegler KA, Romio M, Rigoni G, Carrer A, Biasutto L, Parrasia S, Kadow S, Managò A, Urbani A, Rossa A, Semenzato G, Soriano ME, Trentin L, Ahmad S, Edwards M, Gulbins E, Paradisi C, Zoratti M, Leanza L, Szabò I. Insight into the mechanism of cytotoxicity of membrane-permeant psoralenic Kv1.3 channel inhibitors by chemical dissection of a novel member of the family. Redox Biol 2020; 37:101705. [PMID: 33007503 PMCID: PMC7527709 DOI: 10.1016/j.redox.2020.101705] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2020] [Revised: 08/14/2020] [Accepted: 08/25/2020] [Indexed: 02/06/2023] Open
Abstract
The potassium channel Kv1.3, involved in several important pathologies, is the target of a family of psoralen-based drugs whose mechanism of action is not fully understood. Here we provide evidence for a physical interaction of the mitochondria-located Kv1.3 (mtKv1.3) and Complex I of the respiratory chain and show that this proximity underlies the death-inducing ability of psoralenic Kv1.3 inhibitors. The effects of PAP-1-MHEG (PAP-1, a Kv1.3 inhibitor, with six monomeric ethylene glycol units attached to the phenyl ring of PAP-1), a more soluble novel derivative of PAP-1 and of its various portions on mitochondrial physiology indicate that the psoralenic moiety of PAP-1 bound to mtKv1.3 facilitates the diversion of electrons from Complex I to molecular oxygen. The resulting massive production of toxic Reactive Oxygen Species leads to death of cancer cells expressing Kv1.3. In vivo, PAP-1-MHEG significantly decreased melanoma volume. In summary, PAP-1-MHEG offers insights into the mechanisms of cytotoxicity of this family of compounds and may represent a valuable clinical tool. The mitochondrial channel mitoKv1.3 is a promising pharmacological target. MitoKv1.3 interacts with Complex I of the respiratory chain. Psoralenic inhibitors of Kv1.3 facilitate the diversion of e− from complex I to O2. A novel psoralenic Kv1.3 inhibitor with increased solubility reduces melanoma volume.
Collapse
Affiliation(s)
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Italy
| | | | | | - Matteo Romio
- Department of Chemical Sciences, University of Padua, Italy
| | | | - Andrea Carrer
- Department of Biology, University of Padua, Italy; Department of Biomedical Sciences, University of Padua, Italy
| | - Lucia Biasutto
- Department of Biomedical Sciences, University of Padua, Italy; CNR Institute of Neuroscience, Padua, Italy
| | - Sofia Parrasia
- Department of Biomedical Sciences, University of Padua, Italy
| | - Stephanie Kadow
- Department of Molecular Biology, University of Duisburg-Essen, Germany
| | | | - Andrea Urbani
- Department of Biology, University of Padua, Italy; Department of Biomedical Sciences, University of Padua, Italy
| | - Andrea Rossa
- Department of Chemical Sciences, University of Padua, Italy
| | | | | | | | - Syed Ahmad
- Department of Surgery, Medical School, University of Cincinnati, USA
| | - Michael Edwards
- Department of Surgery, Medical School, University of Cincinnati, USA
| | - Erich Gulbins
- Department of Molecular Biology, University of Duisburg-Essen, Germany
| | | | - Mario Zoratti
- Department of Biomedical Sciences, University of Padua, Italy; CNR Institute of Neuroscience, Padua, Italy
| | - Luigi Leanza
- Department of Biology, University of Padua, Italy
| | - Ildikò Szabò
- Department of Biology, University of Padua, Italy; CNR Institute of Neuroscience, Padua, Italy.
| |
Collapse
|
23
|
Stazi M, D’Este G, Mattarei A, Negro S, Lista F, Rigoni M, Megighian A, Montecucco C. An agonist of the CXCR4 receptor accelerates the recovery from the peripheral neuroparalysis induced by Taipan snake envenomation. PLoS Negl Trop Dis 2020; 14:e0008547. [PMID: 32898186 PMCID: PMC7537909 DOI: 10.1371/journal.pntd.0008547] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2020] [Revised: 10/06/2020] [Accepted: 06/19/2020] [Indexed: 01/15/2023] Open
Abstract
Envenomation by snakes is a major neglected human disease. Hospitalization and use of animal-derived antivenom are the primary therapeutic supports currently available. There is consensus that additional, not expensive, treatments that can be delivered even long after the snake bite are needed. We recently showed that the drug dubbed NUCC-390 shortens the time of recovery from the neuroparalysis caused by traumatic or toxic degeneration of peripheral motor neurons. These syndromes are characterized by the activation of a pro-regenerative molecular axis, consisting of the CXCR4 receptor expressed at the damaged site in neuronal axons and by the release of its ligand CXCL12α, produced by surrounding Schwann cells. This intercellular signaling axis promotes axonal growth and functional recovery from paralysis. NUCC-390 is an agonist of CXCR4 acting similarly to CXCL12α. Here, we have tested its efficacy in a murine model of neuroparalytic envenoming by a Papuan Taipan (Oxyuranus scutellatus) where a degeneration of the motor axon terminals caused by the presynaptic PLA2 toxin Taipoxin, contained in the venom, occurs. Using imaging of the neuromuscular junction and electrophysiological analysis, we found that NUCC-390 administration after injection of either the purified neuroparalytic Taipoxin or the whole Taipan venom, significantly accelerates the recovery from paralysis. These results indicate that NUCC-390, which is non-toxic in mice, should be considered for trials in humans to test its efficacy in accelerating the recovery from the peripheral neuroparalysis induced by Taipans. NUCC-390 should be tested as well in the envenomation by other snakes that cause neuroparalytic syndromes in humans. NUCC-390 could become an additional treatment, common to many snake envenomings, that can be delivered after the bite to reduce death by respiratory deficits and to shorten and improve functional recovery.
Collapse
Affiliation(s)
- Marco Stazi
- Department of Biomedical Sciences, University of Padova, Padova, Italy
| | - Giorgia D’Este
- Department of Biomedical Sciences, University of Padova, Padova, Italy
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Samuele Negro
- Department of Biomedical Sciences, University of Padova, Padova, Italy
| | - Florigio Lista
- Department of Medical and Veterinary Research, the Ministry of Defense, Rome, Italy
| | - Michela Rigoni
- Department of Biomedical Sciences, University of Padova, Padova, Italy
| | - Aram Megighian
- Department of Biomedical Sciences, University of Padova, Padova, Italy
| | - Cesare Montecucco
- Department of Biomedical Sciences, University of Padova, Padova, Italy
- CNR Institute of Neuroscience, Department of Biomedical Sciences, Padua, Italy
| |
Collapse
|
24
|
Li S, Wu Z, Li Y, Tantray I, De Stefani D, Mattarei A, Krishnan G, Gao FB, Vogel H, Lu B. Altered MICOS Morphology and Mitochondrial Ion Homeostasis Contribute to Poly(GR) Toxicity Associated with C9-ALS/FTD. Cell Rep 2020; 32:107989. [PMID: 32755582 PMCID: PMC7433775 DOI: 10.1016/j.celrep.2020.107989] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2019] [Revised: 05/20/2020] [Accepted: 07/14/2020] [Indexed: 12/31/2022] Open
Abstract
Amyotrophic lateral sclerosis (ALS) manifests pathological changes in motor neurons and various other cell types. Compared to motor neurons, the contribution of the other cell types to the ALS phenotypes is understudied. G4C2 repeat expansion in C9ORF72 is the most common genetic cause of ALS along with frontotemporal dementia (C9-ALS/FTD), with increasing evidence supporting repeat-encoded poly(GR) in disease pathogenesis. Here, we show in Drosophila muscle that poly(GR) enters mitochondria and interacts with components of the Mitochondrial Contact Site and Cristae Organizing System (MICOS), altering MICOS dynamics and intra-subunit interactions. This impairs mitochondrial inner membrane structure, ion homeostasis, mitochondrial metabolism, and muscle integrity. Similar mitochondrial defects are observed in patient fibroblasts. Genetic manipulation of MICOS components or pharmacological restoration of ion homeostasis with nigericin effectively rescue the mitochondrial pathology and disease phenotypes in both systems. These results implicate MICOS-regulated ion homeostasis in C9-ALS pathogenesis and suggest potential new therapeutic strategies.
Collapse
Affiliation(s)
- Shuangxi Li
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA,These authors contributed equally
| | - Zhihao Wu
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA,These authors contributed equally,Present address: Department of Biological Sciences, Dedman College of Humanities and Sciences, Southern Methodist University, Dallas TX 75275, USA
| | - Yu Li
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| | - Ishaq Tantray
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| | - Diego De Stefani
- Department of Biomedical Sciences, University of Padova, Via Ugo Bassi 58/B, 35131 Padova, Italy
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via F. Marzolo 5, 35131 Padova, Italy
| | - Gopinath Krishnan
- Department of Neurology, University of Massachusetts Medical School, Worcester, MA 01605, USA
| | - Fen-Biao Gao
- Department of Neurology, University of Massachusetts Medical School, Worcester, MA 01605, USA
| | - Hannes Vogel
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| | - Bingwei Lu
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA,Lead Contact,Correspondence:
| |
Collapse
|
25
|
Parrasia S, Mattarei A, Furlan A, Zoratti M, Biasutto L. Small-Molecule Modulators of Mitochondrial Channels as Chemotherapeutic Agents. Cell Physiol Biochem 2019; 53:11-43. [PMID: 31834993 DOI: 10.33594/000000192] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/10/2019] [Indexed: 11/06/2022] Open
Abstract
Ion channels residing in the inner (IMM) and outer (OMM) mitochondrial membranes are emerging as noteworthy pharmacological targets in oncology. While these aspects have not been investigated for all of them, a role in cancer growth and/or metastasis and/or drug resistance has been shown at least for the IMM-residing Ca2+ uniporter complex and K+- selective mtKV1.3, mtIKCa, mtSKCa and mtTASK-3, and for the OMM Voltage-Dependent Anion Channel (mitochondrial porin). A special case is that of the Mitochondrial Permeability Transition Pore, a large pore which forms in the IMM of severely stressed cells, and which may be exploited to precipitate the death of cancerous cells. Here we briefly discuss the oncological relevance of mitochondria and their channels, and summarize the methods that can be adopted to selectively target these intracellular organelles. We then present an updated list of known mitochondrial channels, and review the pharmacology of those with proven relevance for cancer.
Collapse
Affiliation(s)
- Sofia Parrasia
- Dept. of Biomedical Sciences, University of Padova, Padova, Italy
| | - Andrea Mattarei
- Dept. of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Alberto Furlan
- Dept. of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Mario Zoratti
- Dept. of Biomedical Sciences, University of Padova, Padova, Italy.,CNR Neuroscience Institute, Padova, Italy
| | - Lucia Biasutto
- Dept. of Biomedical Sciences, University of Padova, Padova, Italy, .,CNR Neuroscience Institute, Padova, Italy
| |
Collapse
|
26
|
Zanetti G, Negro S, Megighian A, Mattarei A, Lista F, Fillo S, Rigoni M, Pirazzini M, Montecucco C. A CXCR4 receptor agonist strongly stimulates axonal regeneration after damage. Ann Clin Transl Neurol 2019; 6:2395-2402. [PMID: 31725979 PMCID: PMC6917312 DOI: 10.1002/acn3.50926] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2019] [Revised: 09/30/2019] [Accepted: 10/02/2019] [Indexed: 12/21/2022] Open
Abstract
Objective To test whether the signaling axis CXCL12α‐CXCR4 is activated upon crush/cut of the sciatic nerve and to test the activity of NUCC‐390, a new CXCR4 agonist, in promoting nerve recovery from damage. Methods The sciatic nerve was either crushed or cut. Expression and localization of CXCL12α and CXCR4 were evaluated by imaging with specific antibodies. Their functional involvement in nerve regeneration was determined by antibody‐neutralization of CXCL12α, and by the CXCR4 specific antagonist AMD3100, using as quantitative read‐out the compound muscle action potential (CMAP). NUCC‐390 activity on nerve regeneration was determined by imaging and CMAP recordings. Results CXCR4 is expressed at the injury site within the axonal compartment, whilst its ligand CXCL12α is expressed in Schwann cells. The CXCL12α‐CXCR4 axis is involved in the recovery of neurotransmission of the injured nerve. More importantly, the small molecule NUCC‐390 is a strong promoter of the functional and anatomical recovery of the nerve, by acting very similarly to CXCL12α. This pharmacological action is due to the capability of NUCC‐390 to foster elongation of motor neuron axons both in vitro and in vivo. Interpretation Imaging and electrophysiological data provide novel and compelling evidence that the CXCL12α‐CXCR4 axis is involved in sciatic nerve repair after crush/cut. This makes NUCC‐390 a strong candidate molecule to stimulate nerve repair by promoting axonal elongation. We propose this molecule to be tested in other models of neuronal damage, to lay the basis for clinical trials on the efficacy of NUCC‐390 in peripheral nerve repair in humans.
Collapse
Affiliation(s)
- Giulia Zanetti
- Department of Biomedical Sciences, University of Padua, Padua, Italy
| | - Samuele Negro
- Department of Biomedical Sciences, University of Padua, Padua, Italy
| | - Aram Megighian
- Department of Biomedical Sciences, University of Padua, Padua, Italy.,Padua Neuroscience Center, University of Padua, Padua, Italy
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy
| | | | - Silvia Fillo
- Scientific Department, Army Medical Center, Roma, Italy
| | - Michela Rigoni
- Department of Biomedical Sciences, University of Padua, Padua, Italy
| | - Marco Pirazzini
- Department of Biomedical Sciences, University of Padua, Padua, Italy
| | - Cesare Montecucco
- Department of Biomedical Sciences, University of Padua, Padua, Italy.,CNR Institute of Neuroscience, Padua, Italy
| |
Collapse
|
27
|
Negro S, Zanetti G, Mattarei A, Valentini A, Megighian A, Tombesi G, Zugno A, Dianin V, Pirazzini M, Fillo S, Lista F, Rigoni M, Montecucco C. An Agonist of the CXCR4 Receptor Strongly Promotes Regeneration of Degenerated Motor Axon Terminals. Cells 2019; 8:E1183. [PMID: 31575088 PMCID: PMC6829515 DOI: 10.3390/cells8101183] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2019] [Revised: 09/24/2019] [Accepted: 09/27/2019] [Indexed: 12/19/2022] Open
Abstract
The activation of the G-protein coupled receptor CXCR4 by its ligand CXCL12α is involved in a large variety of physiological and pathological processes, including the growth of B cells precursors and of motor axons, autoimmune diseases, stem cell migration, inflammation, and several neurodegenerative conditions. Recently, we demonstrated that CXCL12α potently stimulates the functional recovery of damaged neuromuscular junctions via interaction with CXCR4. This result prompted us to test the neuroregeneration activity of small molecules acting as CXCR4 agonists, endowed with better pharmacokinetics with respect to the natural ligand. We focused on NUCC-390, recently shown to activate CXCR4 in a cellular system. We designed a novel and convenient chemical synthesis of NUCC-390, which is reported here. NUCC-390 was tested for its capability to induce the regeneration of motor axon terminals completely degenerated by the presynaptic neurotoxin α-Latrotoxin. NUCC-390 was found to strongly promote the functional recovery of the neuromuscular junction, as assayed by electrophysiology and imaging. This action is CXCR4 dependent, as it is completely prevented by AMD3100, a well-characterized CXCR4 antagonist. These data make NUCC-390 a strong candidate to be tested in human therapy to promote nerve recovery of function after different forms of neurodegeneration.
Collapse
Affiliation(s)
- Samuele Negro
- Department of Biomedical Sciences, University of Padua, Padua 35131, Italy.
| | - Giulia Zanetti
- Department of Biomedical Sciences, University of Padua, Padua 35131, Italy.
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua 35131, Italy.
| | - Alice Valentini
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua 35131, Italy.
| | - Aram Megighian
- Department of Biomedical Sciences, University of Padua, Padua 35131, Italy.
- Padua Neuroscience Institute, Padua 35131, Italy.
| | - Giulia Tombesi
- Department of Biology, University of Padua, Padua 35131, Italy.
| | - Alessandro Zugno
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua 35131, Italy.
| | - Valentina Dianin
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua 35131, Italy.
| | - Marco Pirazzini
- Department of Biomedical Sciences, University of Padua, Padua 35131, Italy.
| | - Silvia Fillo
- Center of Medical and Veterinary Research of the Ministry of Defence, Rome 00184, Italy.
| | - Florigio Lista
- Center of Medical and Veterinary Research of the Ministry of Defence, Rome 00184, Italy.
| | - Michela Rigoni
- Department of Biomedical Sciences, University of Padua, Padua 35131, Italy.
| | - Cesare Montecucco
- Department of Biomedical Sciences, University of Padua, Padua 35131, Italy.
- CNR Institute of Neuroscience, Padua 35131, Italy.
| |
Collapse
|
28
|
Costa R, Peruzzo R, Bachmann M, Montà GD, Vicario M, Santinon G, Mattarei A, Moro E, Quintana-Cabrera R, Scorrano L, Zeviani M, Vallese F, Zoratti M, Paradisi C, Argenton F, Brini M, Calì T, Dupont S, Szabò I, Leanza L. Impaired Mitochondrial ATP Production Downregulates Wnt Signaling via ER Stress Induction. Cell Rep 2019; 28:1949-1960.e6. [PMID: 31433973 DOI: 10.1016/j.celrep.2019.07.050] [Citation(s) in RCA: 50] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2018] [Revised: 03/01/2019] [Accepted: 07/16/2019] [Indexed: 02/02/2023] Open
Abstract
Wnt signaling affects fundamental development pathways and, if aberrantly activated, promotes the development of cancers. Wnt signaling is modulated by different factors, but whether the mitochondrial energetic state affects Wnt signaling is unknown. Here, we show that sublethal concentrations of different compounds that decrease mitochondrial ATP production specifically downregulate Wnt/β-catenin signaling in vitro in colon cancer cells and in vivo in zebrafish reporter lines. Accordingly, fibroblasts from a GRACILE syndrome patient and a generated zebrafish model lead to reduced Wnt signaling. We identify a mitochondria-Wnt signaling axis whereby a decrease in mitochondrial ATP reduces calcium uptake into the endoplasmic reticulum (ER), leading to endoplasmic reticulum stress and to impaired Wnt signaling. In turn, the recovery of the ATP level or the inhibition of endoplasmic reticulum stress restores Wnt activity. These findings reveal a mechanism that links mitochondrial energetic metabolism to the control of the Wnt pathway that may be beneficial against several pathologies.
Collapse
Affiliation(s)
- Roberto Costa
- Department of Biology, University of Padova, Padova, Italy
| | | | | | | | - Mattia Vicario
- Department of Biomedical Sciences, University of Padova, Padova, Italy
| | - Giulia Santinon
- Department of Molecular Medicine, University of Padova, Padova, Italy
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Enrico Moro
- Department of Molecular Medicine, University of Padova, Padova, Italy
| | - Rubén Quintana-Cabrera
- Department of Biology, University of Padova, Padova, Italy; Venetian Institute of Molecular Medicine, Padova, Padova, Italy
| | - Luca Scorrano
- Department of Biology, University of Padova, Padova, Italy; Venetian Institute of Molecular Medicine, Padova, Padova, Italy
| | - Massimo Zeviani
- MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK
| | - Francesca Vallese
- Department of Biomedical Sciences, University of Padova, Padova, Italy
| | - Mario Zoratti
- Department of Biomedical Sciences, University of Padova, Padova, Italy; CNR Institute of Neuroscience, Padova, Italy
| | - Cristina Paradisi
- Department of Chemical Sciences, University of Padova, Padova, Italy
| | | | - Marisa Brini
- Department of Biology, University of Padova, Padova, Italy
| | - Tito Calì
- Department of Biomedical Sciences, University of Padova, Padova, Italy
| | - Sirio Dupont
- Department of Molecular Medicine, University of Padova, Padova, Italy
| | - Ildikò Szabò
- Department of Biology, University of Padova, Padova, Italy; CNR Institute of Neuroscience, Padova, Italy.
| | - Luigi Leanza
- Department of Biology, University of Padova, Padova, Italy.
| |
Collapse
|
29
|
Barattin M, Mattarei A, Balasso A, Paradisi C, Cantù L, Del Favero E, Viitala T, Mastrotto F, Caliceti P, Salmaso S. Correction to pH-Controlled Liposomes for Enhanced Cell Penetration in Tumor Environment. ACS Appl Mater Interfaces 2019; 11:29474-29475. [PMID: 31379154 DOI: 10.1021/acsami.9b12730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
|
30
|
Biasutto L, Mattarei A, La Spina M, Azzolini M, Parrasia S, Szabò I, Zoratti M. Strategies to target bioactive molecules to subcellular compartments. Focus on natural compounds. Eur J Med Chem 2019; 181:111557. [PMID: 31374419 DOI: 10.1016/j.ejmech.2019.07.060] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2019] [Revised: 07/04/2019] [Accepted: 07/21/2019] [Indexed: 02/06/2023]
Abstract
Many potential pharmacological targets are present in multiple subcellular compartments and have different pathophysiological roles depending on location. In these cases, selective targeting of a drug to the relevant subcellular domain(s) may help to sharpen its impact by providing topological specificity, thus limiting side effects, and to concentrate the compound where needed, thus increasing its effectiveness. We review here the state of the art in precision subcellular delivery. The major approaches confer "homing" properties to the active principle via permanent or reversible (in pro-drug fashion) modifications, or through the use of special-design nanoparticles or liposomes to ferry a drug(s) cargo to its desired destination. An assortment of peptides, substituents with delocalized positive charges, custom-blended lipid mixtures, pH- or enzyme-sensitive groups provide the main tools of the trade. Mitochondria, lysosomes and the cell membrane may be mentioned as the fronts on which the most significant advances have been made. Most of the examples presented here have to do with targeting natural compounds - in particular polyphenols, known as pleiotropic agents - to one or the other subcellular compartment.
Collapse
Affiliation(s)
- Lucia Biasutto
- CNR Neuroscience Institute, Viale G. Colombo 3, 35121, Padova, Italy; Dept. Biomedical Sciences, University of Padova, Viale G. Colombo 3, 35121, Padova, Italy.
| | - Andrea Mattarei
- Dept. Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo 5, 35131, Padova, Italy
| | - Martina La Spina
- Dept. Biomedical Sciences, University of Padova, Viale G. Colombo 3, 35121, Padova, Italy
| | - Michele Azzolini
- Dept. Biomedical Sciences, University of Padova, Viale G. Colombo 3, 35121, Padova, Italy
| | - Sofia Parrasia
- Dept. Biomedical Sciences, University of Padova, Viale G. Colombo 3, 35121, Padova, Italy
| | - Ildikò Szabò
- CNR Neuroscience Institute, Viale G. Colombo 3, 35121, Padova, Italy; Dept. Biology, University of Padova, Viale G. Colombo 3, 35121, Padova, Italy
| | - Mario Zoratti
- CNR Neuroscience Institute, Viale G. Colombo 3, 35121, Padova, Italy; Dept. Biomedical Sciences, University of Padova, Viale G. Colombo 3, 35121, Padova, Italy
| |
Collapse
|
31
|
Pendin D, Norante R, De Nadai A, Gherardi G, Vajente N, Basso E, Kaludercic N, Mammucari C, Paradisi C, Pozzan T, Mattarei A. A Synthetic Fluorescent Mitochondria‐Targeted Sensor for Ratiometric Imaging of Calcium in Live Cells. Angew Chem Int Ed Engl 2019; 58:9917-9922. [DOI: 10.1002/anie.201902272] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2019] [Revised: 04/23/2019] [Indexed: 12/15/2022]
Affiliation(s)
- Diana Pendin
- Department of Biomedical SciencesUniversity of Padua Via U. Bassi 58/B 35131 Padua Italy
- Neuroscience Institute, Padua SectionNational Research Council Via U. Bassi 58/B 35131 Padua Italy
| | - Rosa Norante
- Department of Biomedical SciencesUniversity of Padua Via U. Bassi 58/B 35131 Padua Italy
| | - Andrea De Nadai
- Department of Chemical Sciences Via F. Marzolo 1 35131 Padua Italy
| | - Gaia Gherardi
- Department of Biomedical SciencesUniversity of Padua Via U. Bassi 58/B 35131 Padua Italy
| | - Nicola Vajente
- Department of Biomedical SciencesUniversity of Padua Via U. Bassi 58/B 35131 Padua Italy
| | - Emy Basso
- Department of Biomedical SciencesUniversity of Padua Via U. Bassi 58/B 35131 Padua Italy
- Neuroscience Institute, Padua SectionNational Research Council Via U. Bassi 58/B 35131 Padua Italy
| | - Nina Kaludercic
- Department of Biomedical SciencesUniversity of Padua Via U. Bassi 58/B 35131 Padua Italy
- Neuroscience Institute, Padua SectionNational Research Council Via U. Bassi 58/B 35131 Padua Italy
| | - Cristina Mammucari
- Department of Biomedical SciencesUniversity of Padua Via U. Bassi 58/B 35131 Padua Italy
| | | | - Tullio Pozzan
- Department of Biomedical SciencesUniversity of Padua Via U. Bassi 58/B 35131 Padua Italy
- Neuroscience Institute, Padua SectionNational Research Council Via U. Bassi 58/B 35131 Padua Italy
- Venetian Institute of Molecular Medicine Via G. Orus 2 35131 Padua Italy
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological SciencesUniversity of Padua Via F. Marzolo 5 35131 Padua Italy
| |
Collapse
|
32
|
Pendin D, Norante R, De Nadai A, Gherardi G, Vajente N, Basso E, Kaludercic N, Mammucari C, Paradisi C, Pozzan T, Mattarei A. A Synthetic Fluorescent Mitochondria‐Targeted Sensor for Ratiometric Imaging of Calcium in Live Cells. Angew Chem Int Ed Engl 2019. [DOI: 10.1002/ange.201902272] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Diana Pendin
- Department of Biomedical SciencesUniversity of Padua Via U. Bassi 58/B 35131 Padua Italy
- Neuroscience Institute, Padua SectionNational Research Council Via U. Bassi 58/B 35131 Padua Italy
| | - Rosa Norante
- Department of Biomedical SciencesUniversity of Padua Via U. Bassi 58/B 35131 Padua Italy
| | - Andrea De Nadai
- Department of Chemical Sciences Via F. Marzolo 1 35131 Padua Italy
| | - Gaia Gherardi
- Department of Biomedical SciencesUniversity of Padua Via U. Bassi 58/B 35131 Padua Italy
| | - Nicola Vajente
- Department of Biomedical SciencesUniversity of Padua Via U. Bassi 58/B 35131 Padua Italy
| | - Emy Basso
- Department of Biomedical SciencesUniversity of Padua Via U. Bassi 58/B 35131 Padua Italy
- Neuroscience Institute, Padua SectionNational Research Council Via U. Bassi 58/B 35131 Padua Italy
| | - Nina Kaludercic
- Department of Biomedical SciencesUniversity of Padua Via U. Bassi 58/B 35131 Padua Italy
- Neuroscience Institute, Padua SectionNational Research Council Via U. Bassi 58/B 35131 Padua Italy
| | - Cristina Mammucari
- Department of Biomedical SciencesUniversity of Padua Via U. Bassi 58/B 35131 Padua Italy
| | | | - Tullio Pozzan
- Department of Biomedical SciencesUniversity of Padua Via U. Bassi 58/B 35131 Padua Italy
- Neuroscience Institute, Padua SectionNational Research Council Via U. Bassi 58/B 35131 Padua Italy
- Venetian Institute of Molecular Medicine Via G. Orus 2 35131 Padua Italy
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological SciencesUniversity of Padua Via F. Marzolo 5 35131 Padua Italy
| |
Collapse
|
33
|
Barattin M, Mattarei A, Balasso A, Paradisi C, Cantù L, Del Favero E, Viitala T, Mastrotto F, Caliceti P, Salmaso S. pH-Controlled Liposomes for Enhanced Cell Penetration in Tumor Environment. ACS Appl Mater Interfaces 2018; 10:17646-17661. [PMID: 29737834 DOI: 10.1021/acsami.8b03469] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
An innovative pH-switchable colloidal system that can be exploited for site-selective anticancer drug delivery has been generated by liposome decoration with a new novel synthetic non-peptidic oligo-arginine cell-penetration enhancer (CPE) and a quenching PEGylated counterpart that detaches from the vesicle surface under the acidic conditions of tumors. The CPE module ( Arg4- DAG) is formed by four arginine units conjugated to a first-generation (G1) 2,2-bis(hydroxymethyl)propionic acid (bis-MPA)/2,2-bis(aminomethyl)propionic acid (bis-AMPA) polyester dendron terminating with 1,2-distearoyl-3-azidopropane for liposome bilayer insertion. The zeta potential of the Arg4- DAG-decorated liposomes increased up to +32 mV as the Arg4- DAG/lipids molar ratio increased. The Arg4- DAG liposome shielding at pH 7.4 was provided by methoxy-PEG5 kDa-polymethacryloyl sulfadimethoxine (mPEG5 kDa-SDM8) with 7.1 apparent p Ka. Zeta potential, surface plasmon resonance and synchrotron small-angle X-ray scattering analyses showed that at pH 7.4 mPEG5 kDa-SDM8 associates with polycationic Arg4- DAG-decorated liposomes yielding liposomes with neutral zeta potential. At pH 6.5, which mimics the tumor environment, mPEG5 kDa-SDM8 detaches from the liposome surface yielding Arg4- DAG exposure. Flow cytometry and confocal microscopy showed a 30-fold higher HeLa cancer cell association of the Arg4- DAG-decorated liposomes compared to non-decorated liposomes. At pH 7.4, the mPEG5 kDa-SDM8-coated liposomes undergo low cell association while remarkable cell association occurred at pH 6.5, which allowed for the controlled intracellular delivery of model macromolecules and small molecules loaded in the liposome under tumor conditions.
Collapse
Affiliation(s)
- Michela Barattin
- Department of Pharmaceutical and Pharmacological Sciences , University of Padova , Via F. Marzolo 5 , Padova 35131 , Italy
| | - Andrea Mattarei
- Department of Chemical Sciences , University of Padova , Via F. Marzolo 1 , Padova 35131 , Italy
| | - Anna Balasso
- Department of Pharmaceutical and Pharmacological Sciences , University of Padova , Via F. Marzolo 5 , Padova 35131 , Italy
| | - Cristina Paradisi
- Department of Chemical Sciences , University of Padova , Via F. Marzolo 1 , Padova 35131 , Italy
| | - Laura Cantù
- Department of Medical Biotechnologies and Traslational Medicine , University of Milano , LITA, Via F.lli Cervi, 93 , Segrate 20090 , Italy
| | - Elena Del Favero
- Department of Medical Biotechnologies and Traslational Medicine , University of Milano , LITA, Via F.lli Cervi, 93 , Segrate 20090 , Italy
| | - Tapani Viitala
- Centre for Drug Research and Division of Pharmaceutical Biosciences, Faculty of Pharmacy , University of Helsinki , Viikinkaari 5 , Helsinki FI-00014 , Finland
| | - Francesca Mastrotto
- Department of Pharmaceutical and Pharmacological Sciences , University of Padova , Via F. Marzolo 5 , Padova 35131 , Italy
| | - Paolo Caliceti
- Department of Pharmaceutical and Pharmacological Sciences , University of Padova , Via F. Marzolo 5 , Padova 35131 , Italy
| | - Stefano Salmaso
- Department of Pharmaceutical and Pharmacological Sciences , University of Padova , Via F. Marzolo 5 , Padova 35131 , Italy
| |
Collapse
|
34
|
Mattarei A, Romio M, Managò A, Zoratti M, Paradisi C, Szabò I, Leanza L, Biasutto L. Novel Mitochondria-Targeted Furocoumarin Derivatives as Possible Anti-Cancer Agents. Front Oncol 2018; 8:122. [PMID: 29740538 PMCID: PMC5925966 DOI: 10.3389/fonc.2018.00122] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2018] [Accepted: 04/04/2018] [Indexed: 01/10/2023] Open
Abstract
Targeting small molecules to appropriate subcellular compartments is a way to increase their selectivity and effectiveness while minimizing side effects. This can be accomplished either by stably incorporating specific "homing" properties into the structure of the active principle, or by attaching to it a targeting moiety via a labile linker, i.e., by producing a "targeting pro-drug." Mitochondria are a recognized therapeutic target in oncology, and blocking the population of the potassium channel Kv1.3 residing in the inner mitochondrial membrane (mtKv1.3) has been shown to cause apoptosis of cancerous cells expressing it. These concepts have led us to devise novel, mitochondria-targeted, membrane-permeant drug candidates containing the furocoumarin (psoralenic) ring system and the triphenylphosphonium (TPP) lipophilic cation. The strategy has proven effective in various cancer models, including pancreatic ductal adenocarcinoma, melanoma, and glioblastoma, stimulating us to devise further novel molecules to extend and diversify the range of available drugs of this type. New compounds were synthesized and tested in vitro; one of them-a prodrug in which the coumarinic moiety and the TPP group are linked by a bridge comprising a labile carbonate bond system-proved quite effective in in vitro cytotoxicity assays. Selective death induction is attributed to inhibition of mtKv1.3. This results in oxidative stress, which is fatal for the already-stressed malignant cells. This compound may thus be a candidate drug for the mtKv1.3-targeting therapeutic approach.
Collapse
Affiliation(s)
- Andrea Mattarei
- Department of Chemical Sciences, University of Padova, Padova, Italy
| | - Matteo Romio
- Department of Chemical Sciences, University of Padova, Padova, Italy
| | | | - Mario Zoratti
- CNR Neuroscience Institute, Padova, Italy.,Department of Biomedical Sciences, University of Padova, Padova, Italy
| | - Cristina Paradisi
- Department of Chemical Sciences, University of Padova, Padova, Italy
| | - Ildikò Szabò
- Department of Biology, University of Padova, Padova, Italy
| | - Luigi Leanza
- Department of Biology, University of Padova, Padova, Italy
| | - Lucia Biasutto
- CNR Neuroscience Institute, Padova, Italy.,Department of Biomedical Sciences, University of Padova, Padova, Italy
| |
Collapse
|
35
|
Austin S, Tavakoli M, Pfeiffer C, Seifert J, Mattarei A, De Stefani D, Zoratti M, Nowikovsky K. LETM1-Mediated K + and Na + Homeostasis Regulates Mitochondrial Ca 2+ Efflux. Front Physiol 2017; 8:839. [PMID: 29204122 PMCID: PMC5698270 DOI: 10.3389/fphys.2017.00839] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2017] [Accepted: 10/09/2017] [Indexed: 12/13/2022] Open
Abstract
Ca2+ transport across the inner membrane of mitochondria (IMM) is of major importance for their functions in bioenergetics, cell death and signaling. It is therefore tightly regulated. It has been recently proposed that LETM1—an IMM protein with a crucial role in mitochondrial K+/H+ exchange and volume homeostasis—also acts as a Ca2+/H+ exchanger. Here we show for the first time that lowering LETM1 gene expression by shRNA hampers mitochondrial K+/H+ and Na+/H+ exchange. Decreased exchange activity resulted in matrix K+ accumulation in these mitochondria. Furthermore, LETM1 depletion selectively decreased Na+/Ca2+ exchange mediated by NCLX, as observed in the presence of ruthenium red, a blocker of the Mitochondrial Ca2+ Uniporter (MCU). These data confirm a key role of LETM1 in monovalent cation homeostasis, and suggest that the effects of its modulation on mitochondrial transmembrane Ca2+ fluxes may reflect those on Na+/H+ exchange activity.
Collapse
Affiliation(s)
- Shane Austin
- Department of Internal Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Mojtaba Tavakoli
- Department of Internal Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Christina Pfeiffer
- Department of Internal Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Julia Seifert
- Department of Internal Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Andrea Mattarei
- Department of Chemical Sciences, Università di Padova, Padova, Italy
| | - Diego De Stefani
- Department of Biomedical Sciences, Università di Padova, Padova, Italy
| | - Mario Zoratti
- Department of Biomedical Sciences, Università di Padova, Padova, Italy.,Institute of Neuroscience (CNR), Padova, Italy
| | - Karin Nowikovsky
- Department of Internal Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
36
|
Sassi N, Mattarei A, Espina V, Liotta L, Zoratti M, Paradisi C, Biasutto L. Potential anti-cancer activity of 7- O -pentyl quercetin: Efficient, membrane-targeted kinase inhibition and pro-oxidant effect. Pharmacol Res 2017; 124:9-19. [DOI: 10.1016/j.phrs.2017.07.016] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2017] [Revised: 07/04/2017] [Accepted: 07/14/2017] [Indexed: 12/14/2022]
|
37
|
Peruzzo R, Mattarei A, Romio M, Paradisi C, Zoratti M, Szabò I, Leanza L. Regulation of Proliferation by a Mitochondrial Potassium Channel in Pancreatic Ductal Adenocarcinoma Cells. Front Oncol 2017; 7:239. [PMID: 29034212 PMCID: PMC5626813 DOI: 10.3389/fonc.2017.00239] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2017] [Accepted: 09/19/2017] [Indexed: 12/21/2022] Open
Abstract
Previous results link the mitochondrial potassium channel Kv1.3 (mitoKv1.3) to the regulation of apoptosis. By synthesizing new, mitochondria-targeted derivatives (PAPTP and PCARBTP) of PAP-1, a specific membrane-permeant Kv1.3 inhibitor, we have recently provided evidence that both drugs acting on mitoKv1.3 are able to induce apoptosis and reduce tumor growth in vivo without affecting healthy tissues and cells. In the present article, by exploiting these new drugs, we addressed the question whether mitoKv1.3 contributes to the regulation of cell proliferation as well. When used at low concentrations, which do not compromise cell survival, both drugs slightly increased the percentage of cells in S phase while decreased the population at G0/G1 stage of cells from two different pancreatic ductal adenocarcinoma lines. Our data suggest that the observed modulation is related to ROS levels within the cells, opening the way to link mitochondrial ion channel function to downstream, ROS-related signaling events that might be important for cell cycle progression.
Collapse
Affiliation(s)
| | - Andrea Mattarei
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Matteo Romio
- Department of Chemical Sciences, University of Padova, Padova, Italy
| | - Cristina Paradisi
- Department of Chemical Sciences, University of Padova, Padova, Italy
| | - Mario Zoratti
- Institute of Neuroscience, CNR, Padova, Italy.,Department of Biomedical Sciences, University of Padova, Padova, Italy
| | - Ildikò Szabò
- Department of Biology, University of Padova, Padova, Italy.,Institute of Neuroscience, CNR, Padova, Italy
| | - Luigi Leanza
- Department of Biology, University of Padova, Padova, Italy
| |
Collapse
|
38
|
Venturini E, Leanza L, Azzolini M, Kadow S, Mattarei A, Weller M, Tabatabai G, Edwards M, Zoratti M, Paradisi C, Szabò I, Gulbins E, Becker K. Targeting the Potassium Channel Kv1.3 Kills Glioblastoma Cells. Neurosignals 2017; 25:26-38. [DOI: 10.1159/000480643] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2017] [Accepted: 08/24/2017] [Indexed: 11/19/2022] Open
|
39
|
Mattarei A, Enzinger M, Gu S, Karunakaran MM, Kimmel B, Berner N, Adams EJ, Herrmann T, Amslinger S. A Photo-Crosslinkable Biotin Derivative of the Phosphoantigen (E)-4-Hydroxy-3-Methylbut-2-Enyl Diphosphate (HMBPP) Activates Vγ9Vδ2 T Cells and Binds to the HMBPP Site of BTN3A1. Chemistry 2017. [PMID: 28631855 DOI: 10.1002/chem.201702650] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Vγ9Vδ2 T cells play an important role in the cross talk of the innate and adaptive immune system. For their activation by phosphoantigens (PAgs), both cell surface receptors, the eponymous Vγ9Vδ2 T cell antigen receptors (Vγ9Vδ2 TCRs) on Vγ9Vδ2 T cells and butyrophilin 3A1 (BTN3A1) on the phosphoantigen-"presenting" cell, are mandatory. To find yet undetected but further contributing proteins, a biotinylated, photo-crosslinkable benzophenone probe BioBP-HMBPP (2) was synthesized from a known allyl alcohol in nine steps and overall 16 % yield. 2 is based on the picomolar PAg (E)-4-hydroxy-3-methylbut-2-enyl diphosphate (HMBPP, 1). Laser irradiation of 2 at 308 nm initiated the photo-crosslinking reaction with proteins. When the B30.2 domain of BTN3A1, which contains a positively charged PAg-binding pocket, was exposed to increasing amounts of HMBPP (1), labeling by BioBP-HMBPP (2) was reduced significantly. Because BSA labeling was not impaired, 2 clearly binds to the same site as natural ligand 1. Thus, BioBP-HMBPP (2) is a suitable tool to identify co-ligands or receptors involved in PAg-mediated T cell activation.
Collapse
Affiliation(s)
- Andrea Mattarei
- Institut für Organische Chemie, Universität Regensburg, Universitätsstraße 31, 93053, Regensburg, Germany.,Dipartimento di Scienze Chimiche, Università degli Studi di Padova, Via Marzolo, 1, 35131, Padova, Italy
| | - Monika Enzinger
- Institut für Organische Chemie, Universität Regensburg, Universitätsstraße 31, 93053, Regensburg, Germany
| | - Siyi Gu
- Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, IL, USA
| | - Mohindar Murugesh Karunakaran
- Institut für Virologie und Immunbiologie, Julius-Maximilians-Universität Würzburg, Versbacherstr. 7, 97078, Würzburg, Germany
| | - Brigitte Kimmel
- Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Germany
| | - Nicole Berner
- Institut für Physikalische und Theoretische Chemie, Universität Regensburg, Universitätsstraße 31, 93053, Regensburg, Germany
| | - Erin J Adams
- Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, IL, USA
| | - Thomas Herrmann
- Institut für Virologie und Immunbiologie, Julius-Maximilians-Universität Würzburg, Versbacherstr. 7, 97078, Würzburg, Germany
| | - Sabine Amslinger
- Institut für Organische Chemie, Universität Regensburg, Universitätsstraße 31, 93053, Regensburg, Germany
| |
Collapse
|
40
|
Biasutto L, Mattarei A, Azzolini M, La Spina M, Sassi N, Romio M, Paradisi C, Zoratti M. Resveratrol derivatives as a pharmacological tool. Ann N Y Acad Sci 2017; 1403:27-37. [PMID: 28675763 DOI: 10.1111/nyas.13401] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2017] [Revised: 05/05/2017] [Accepted: 05/10/2017] [Indexed: 12/13/2022]
Abstract
Prodrugs of resveratrol are under development. Among the long-term goals, still largely elusive, are (1) modulating physical properties (e.g., water-soluble derivatives bearing polyethylene glycol chains), (2) changing distribution in the body (e.g., galactosyl derivatives restricted to the intestinal lumen), (3) increasing absorption from the gastrointestinal tract (e.g., derivatives imitating the natural substrates of endogenous transporters), and (4) hindering phase II metabolism (e.g., temporarily blocking the hydroxyls), all contributing to (5) increasing bioavailability. The chemical bonds that have been tested for functionalization include carboxyester, acetal, and carbamate groups. A second approach, which can be combined with the first, seeks to reinforce or modify the biochemical activities of resveratrol by concentrating the compound at specific subcellular sites. An example is provided by mitochondria-targeted derivatives. These proved to be pro-oxidant and cytotoxic in vitro, selectively killing fast-growing and tumor cells when supplied in the low micromolar range. This suggests the possibility of anticancer applications.
Collapse
Affiliation(s)
- Lucia Biasutto
- CNR Neuroscience Institute, Padova, Italy.,Department of Biomedical Sciences, University of Padova, Padova, Italy
| | - Andrea Mattarei
- Department of Chemical Sciences, University of Padova, Padova, Italy.,Department of Pharmaceutical & Pharmacological Sciences, University of Padova, Padova, Italy
| | - Michele Azzolini
- CNR Neuroscience Institute, Padova, Italy.,Department of Biomedical Sciences, University of Padova, Padova, Italy
| | - Martina La Spina
- CNR Neuroscience Institute, Padova, Italy.,Department of Biomedical Sciences, University of Padova, Padova, Italy
| | - Nicola Sassi
- CNR Neuroscience Institute, Padova, Italy.,Department of Biomedical Sciences, University of Padova, Padova, Italy
| | - Matteo Romio
- Department of Chemical Sciences, University of Padova, Padova, Italy
| | - Cristina Paradisi
- Department of Chemical Sciences, University of Padova, Padova, Italy
| | - Mario Zoratti
- CNR Neuroscience Institute, Padova, Italy.,Department of Biomedical Sciences, University of Padova, Padova, Italy
| |
Collapse
|
41
|
Mattarei A, Rossa A, Bombardelli V, Azzolini M, La Spina M, Paradisi C, Zoratti M, Biasutto L. Novel lipid-mimetic prodrugs delivering active compounds to adipose tissue. Eur J Med Chem 2017; 135:77-88. [DOI: 10.1016/j.ejmech.2017.04.034] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2017] [Revised: 03/20/2017] [Accepted: 04/11/2017] [Indexed: 02/07/2023]
|
42
|
Leanza L, Romio M, Becker KA, Azzolini M, Trentin L, Managò A, Venturini E, Zaccagnino A, Mattarei A, Carraretto L, Urbani A, Kadow S, Biasutto L, Martini V, Severin F, Peruzzo R, Trimarco V, Egberts JH, Hauser C, Visentin A, Semenzato G, Kalthoff H, Zoratti M, Gulbins E, Paradisi C, Szabo I. Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In Vivo. Cancer Cell 2017; 31:516-531.e10. [PMID: 28399409 DOI: 10.1016/j.ccell.2017.03.003] [Citation(s) in RCA: 122] [Impact Index Per Article: 17.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/25/2016] [Revised: 02/03/2017] [Accepted: 03/07/2017] [Indexed: 12/13/2022]
Abstract
The potassium channel Kv1.3 is highly expressed in the mitochondria of various cancerous cells. Here we show that direct inhibition of Kv1.3 using two mitochondria-targeted inhibitors alters mitochondrial function and leads to reactive oxygen species (ROS)-mediated death of even chemoresistant cells independently of p53 status. These inhibitors killed 98% of ex vivo primary chronic B-lymphocytic leukemia tumor cells while sparing healthy B cells. In orthotopic mouse models of melanoma and pancreatic ductal adenocarcinoma, the compounds reduced tumor size by more than 90% and 60%, respectively, while sparing immune and cardiac functions. Our work provides direct evidence that specific pharmacological targeting of a mitochondrial potassium channel can lead to ROS-mediated selective apoptosis of cancer cells in vivo, without causing significant side effects.
Collapse
Affiliation(s)
- Luigi Leanza
- Department of Biology, University of Padova, viale G. Colombo 3, 35121 Padova, Italy
| | - Matteo Romio
- Department of Chemical Sciences, University of Padova, via F. Marzolo 1, 35121 Padova, Italy
| | - Katrin Anne Becker
- Department of Molecular Biology, University of Duisburg-Essen, Hufelandstrasse 55, 45122 Essen, Germany
| | - Michele Azzolini
- Department of Biomedical Sciences, University of Padova, viale G. Colombo 3, 35121 Padova, Italy; CNR Institute of Neuroscience, viale G. Colombo 3, 35121 Padova, Italy
| | - Livio Trentin
- Department of Medicine, Hematology and Immunological Branch, University of Padova, and Venetian Institute for Molecular Medicine (VIMM), via G. Orus 2, 35129 Padova, Italy
| | - Antonella Managò
- Department of Biology, University of Padova, viale G. Colombo 3, 35121 Padova, Italy
| | - Elisa Venturini
- Department of Molecular Biology, University of Duisburg-Essen, Hufelandstrasse 55, 45122 Essen, Germany
| | - Angela Zaccagnino
- Institute for Experimental Cancer Research, Medical Faculty, CAU, Kiel, and Department of Surgery, UKSH, Campus Kiel, Arnold-Heller-Strasse 3 (Haus 17), 24105 Kiel, Germany
| | - Andrea Mattarei
- Department of Chemical Sciences, University of Padova, via F. Marzolo 1, 35121 Padova, Italy
| | - Luca Carraretto
- Department of Biology, University of Padova, viale G. Colombo 3, 35121 Padova, Italy
| | - Andrea Urbani
- Department of Biology, University of Padova, viale G. Colombo 3, 35121 Padova, Italy
| | - Stephanie Kadow
- Department of Molecular Biology, University of Duisburg-Essen, Hufelandstrasse 55, 45122 Essen, Germany
| | - Lucia Biasutto
- Department of Biomedical Sciences, University of Padova, viale G. Colombo 3, 35121 Padova, Italy; CNR Institute of Neuroscience, viale G. Colombo 3, 35121 Padova, Italy
| | - Veronica Martini
- Department of Medicine, Hematology and Immunological Branch, University of Padova, and Venetian Institute for Molecular Medicine (VIMM), via G. Orus 2, 35129 Padova, Italy
| | - Filippo Severin
- Department of Medicine, Hematology and Immunological Branch, University of Padova, and Venetian Institute for Molecular Medicine (VIMM), via G. Orus 2, 35129 Padova, Italy
| | - Roberta Peruzzo
- Department of Biology, University of Padova, viale G. Colombo 3, 35121 Padova, Italy
| | - Valentina Trimarco
- Department of Medicine, Hematology and Immunological Branch, University of Padova, and Venetian Institute for Molecular Medicine (VIMM), via G. Orus 2, 35129 Padova, Italy
| | - Jan-Hendrik Egberts
- Institute for Experimental Cancer Research, Medical Faculty, CAU, Kiel, and Department of Surgery, UKSH, Campus Kiel, Arnold-Heller-Strasse 3 (Haus 17), 24105 Kiel, Germany
| | - Charlotte Hauser
- Institute for Experimental Cancer Research, Medical Faculty, CAU, Kiel, and Department of Surgery, UKSH, Campus Kiel, Arnold-Heller-Strasse 3 (Haus 17), 24105 Kiel, Germany
| | - Andrea Visentin
- Department of Medicine, Hematology and Immunological Branch, University of Padova, and Venetian Institute for Molecular Medicine (VIMM), via G. Orus 2, 35129 Padova, Italy
| | - Gianpietro Semenzato
- Department of Medicine, Hematology and Immunological Branch, University of Padova, and Venetian Institute for Molecular Medicine (VIMM), via G. Orus 2, 35129 Padova, Italy
| | - Holger Kalthoff
- Institute for Experimental Cancer Research, Medical Faculty, CAU, Kiel, and Department of Surgery, UKSH, Campus Kiel, Arnold-Heller-Strasse 3 (Haus 17), 24105 Kiel, Germany
| | - Mario Zoratti
- Department of Biomedical Sciences, University of Padova, viale G. Colombo 3, 35121 Padova, Italy; CNR Institute of Neuroscience, viale G. Colombo 3, 35121 Padova, Italy
| | - Erich Gulbins
- Department of Molecular Biology, University of Duisburg-Essen, Hufelandstrasse 55, 45122 Essen, Germany; Department of Surgery, University of Cincinnati, 231 Albert Sabin Way, Cincinnati, OH 45267-0558, USA.
| | - Cristina Paradisi
- Department of Chemical Sciences, University of Padova, via F. Marzolo 1, 35121 Padova, Italy.
| | - Ildiko Szabo
- Department of Biology, University of Padova, viale G. Colombo 3, 35121 Padova, Italy; CNR Institute of Neuroscience, viale G. Colombo 3, 35121 Padova, Italy.
| |
Collapse
|
43
|
Azzolini M, Mattarei A, La Spina M, Fanin M, Chiodarelli G, Romio M, Zoratti M, Paradisi C, Biasutto L. New natural amino acid-bearing prodrugs boost pterostilbene's oral pharmacokinetic and distribution profile. Eur J Pharm Biopharm 2017; 115:149-158. [PMID: 28254379 DOI: 10.1016/j.ejpb.2017.02.017] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Revised: 02/17/2017] [Accepted: 02/24/2017] [Indexed: 12/14/2022]
Abstract
The biomedical effects of the natural phenol pterostilbene are of great interest but its bioavailability is negatively affected by the phenolic group in position 4' which is an ideal target for the conjugative enzymes of phase II metabolism. We report the synthesis and characterization of prodrugs in which the hydroxyl moiety is reversibly protected as a carbamate ester linked to the N-terminus of a natural amino acid. Prodrugs comprising amino acids with hydrophobic side chains were readily absorbed after intragastric administration to rats. The Area Under the Curve for pterostilbene in blood was optimal when prodrugs with isoleucine or β-alanine were used. The prodrug incorporating isoleucine was used for further studies to map distribution into major organs. When compared to pterostilbene itself, administration of the isoleucine prodrug afforded increased absorption, reduced metabolism and higher concentrations of pterostilbene, sustained for several hours, in most of the organs examined. Experiments using Caco-2 cells as an in vitro model for human intestinal absorption suggest that the prodrug could have promising absorption profiles also in humans; its uptake is partly due to passive diffusion, and partly mediated by H+-dependent transporters expressed on the apical membrane of enterocytes, such as PepT1 and OATP.
Collapse
Affiliation(s)
- Michele Azzolini
- University of Padova, Department of Biomedical Sciences, Viale G. Colombo 3, 35121 Padova, Italy; CNR Neuroscience Institute, Viale G. Colombo 3, 35121 Padova, Italy
| | - Andrea Mattarei
- University of Padova, Department of Chemical Sciences, Via F. Marzolo 1, 35131 Padova, Italy
| | - Martina La Spina
- University of Padova, Department of Biomedical Sciences, Viale G. Colombo 3, 35121 Padova, Italy
| | - Michele Fanin
- University of Padova, Department of Chemical Sciences, Via F. Marzolo 1, 35131 Padova, Italy
| | - Giacomo Chiodarelli
- University of Padova, Department of Chemical Sciences, Via F. Marzolo 1, 35131 Padova, Italy
| | - Matteo Romio
- University of Padova, Department of Chemical Sciences, Via F. Marzolo 1, 35131 Padova, Italy
| | - Mario Zoratti
- University of Padova, Department of Biomedical Sciences, Viale G. Colombo 3, 35121 Padova, Italy; CNR Neuroscience Institute, Viale G. Colombo 3, 35121 Padova, Italy
| | - Cristina Paradisi
- University of Padova, Department of Chemical Sciences, Via F. Marzolo 1, 35131 Padova, Italy
| | - Lucia Biasutto
- University of Padova, Department of Biomedical Sciences, Viale G. Colombo 3, 35121 Padova, Italy; CNR Neuroscience Institute, Viale G. Colombo 3, 35121 Padova, Italy.
| |
Collapse
|
44
|
Pirazzini M, Tehran DA, Zanetti G, Leka O, Binz T, Lista F, Mattarei A, Rossetto O, Montecucco C. Hsp90, thioredoxin, and thioredoxin reductase form a chaperone-redox machinery enabling the catalytic activity of clostridial neurotoxins inside nerve terminals. Toxicon 2016. [DOI: 10.1016/j.toxicon.2016.11.191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
45
|
Azarnia Tehran D, Pirazzini M, Leka O, Mattarei A, Lista F, Binz T, Rossetto O, Montecucco C. Hsp90 is involved in the entry of clostridial neurotoxins into the cytosol of nerve terminals. Cell Microbiol 2016; 19. [DOI: 10.1111/cmi.12647] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2016] [Revised: 07/06/2016] [Accepted: 07/08/2016] [Indexed: 12/31/2022]
Affiliation(s)
- Domenico Azarnia Tehran
- Department of Biomedical Sciences; University of Padova; Via Ugo Bassi 58/B 35121 Padova Italy
| | - Marco Pirazzini
- Department of Biomedical Sciences; University of Padova; Via Ugo Bassi 58/B 35121 Padova Italy
| | - Oneda Leka
- Department of Biomedical Sciences; University of Padova; Via Ugo Bassi 58/B 35121 Padova Italy
| | - Andrea Mattarei
- Department of Chemical Sciences; University of Padova; Via F. Marzolo 1 35131 Padova Italy
| | - Florigio Lista
- Histology and Molecular Biology Section; Army Medical and Veterinary Research Center; Via Santo Stefano Rotondo 4 00184 Rome Italy
| | - Thomas Binz
- Medizinische Hochschule Hannover; Institut für Physiologische Chemie OE4310; 30625 Hannover Germany
| | - Ornella Rossetto
- Department of Biomedical Sciences; University of Padova; Via Ugo Bassi 58/B 35121 Padova Italy
| | - Cesare Montecucco
- Department of Biomedical Sciences; University of Padova; Via Ugo Bassi 58/B 35121 Padova Italy
- National Research Institute of Neuroscience; University of Padova; Via Ugo Bassi 58/B 35121 Padova Italy
| |
Collapse
|
46
|
Schnell L, Mittler AK, Mattarei A, Azarnia Tehran D, Montecucco C, Barth H. Semicarbazone EGA Inhibits Uptake of Diphtheria Toxin into Human Cells and Protects Cells from Intoxication. Toxins (Basel) 2016; 8:toxins8070221. [PMID: 27428999 PMCID: PMC4963853 DOI: 10.3390/toxins8070221] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2016] [Revised: 06/25/2016] [Accepted: 07/07/2016] [Indexed: 01/29/2023] Open
Abstract
Diphtheria toxin is a single-chain protein toxin that invades human cells by receptor-mediated endocytosis. In acidic endosomes, its translocation domain inserts into endosomal membranes and facilitates the transport of the catalytic domain (DTA) from endosomal lumen into the host cell cytosol. Here, DTA ADP-ribosylates elongation factor 2 inhibits protein synthesis and leads to cell death. The compound 4-bromobenzaldehyde N-(2,6-dimethylphenyl)semicarbazone (EGA) has been previously shown to protect cells from various bacterial protein toxins which deliver their enzymatic subunits from acidic endosomes to the cytosol, including Bacillus anthracis lethal toxin and the binary clostridial actin ADP-ribosylating toxins C2, iota and Clostridium difficile binary toxin (CDT). Here, we demonstrate that EGA also protects human cells from diphtheria toxin by inhibiting the pH-dependent translocation of DTA across cell membranes. The results suggest that EGA might serve for treatment and/or prevention of the severe disease diphtheria.
Collapse
Affiliation(s)
- Leonie Schnell
- Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Albert-Einstein-Allee 11, 89081 Ulm, Germany.
| | - Ann-Katrin Mittler
- Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Albert-Einstein-Allee 11, 89081 Ulm, Germany.
| | - Andrea Mattarei
- Department of Chemical Sciences, University of Padova, 35121 Padova, Italy.
| | | | - Cesare Montecucco
- Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy.
| | - Holger Barth
- Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Albert-Einstein-Allee 11, 89081 Ulm, Germany.
| |
Collapse
|
47
|
Azarnia Tehran D, Zanetti G, Leka O, Lista F, Fillo S, Binz T, Shone CC, Rossetto O, Montecucco C, Paradisi C, Mattarei A, Pirazzini M. A Novel Inhibitor Prevents the Peripheral Neuroparalysis of Botulinum Neurotoxins. Sci Rep 2015; 5:17513. [PMID: 26670952 PMCID: PMC4680858 DOI: 10.1038/srep17513] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2015] [Accepted: 10/30/2015] [Indexed: 11/17/2022] Open
Abstract
Botulinum neurotoxins (BoNTs) form a large class of potent and deadly neurotoxins. Given their growing number, it is of paramount importance to discover novel inhibitors targeting common steps of their intoxication process. Recently, EGA was shown to inhibit the action of bacterial toxins and viruses exhibiting a pH-dependent translocation step in mammalian cells, by interfering with their entry route. As BoNTs act in the cytosol of nerve terminals, the entry into an appropriate compartment wherefrom they translocate the catalytic moiety is essential for toxicity. Herein we propose an optimized procedure to synthesize EGA and we show that, in vitro, it prevents the neurotoxicity of different BoNT serotypes by interfering with their trafficking. Furthermore, in mice, EGA mitigates botulism symptoms induced by BoNT/A and significantly decreases the lethality of BoNT/B and BoNT/D. This opens the possibility of using EGA as a lead compound to develop novel inhibitors of botulinum neurotoxins.
Collapse
Affiliation(s)
| | - Giulia Zanetti
- Department of Biomedical Sciences, Via U. Bassi 58/B, 35121, Padova, Italy
| | - Oneda Leka
- Department of Biomedical Sciences, Via U. Bassi 58/B, 35121, Padova, Italy
| | - Florigio Lista
- Histology and Molecular Biology Section, Army Medical and Veterinary Research Center, Via Santo Stefano Rotondo 4, 00184 Roma, Italy
| | - Silvia Fillo
- Histology and Molecular Biology Section, Army Medical and Veterinary Research Center, Via Santo Stefano Rotondo 4, 00184 Roma, Italy
| | - Thomas Binz
- Institut für Biochemie, OE 4310, Medizinische Hochschule Hannover, 30623 Hannover, Germany
| | - Clifford C. Shone
- Public Health England, Porton Down, Salisbury, Wiltshire, SP4 OJG, UK
| | - Ornella Rossetto
- Department of Biomedical Sciences, Via U. Bassi 58/B, 35121, Padova, Italy
| | - Cesare Montecucco
- Department of Biomedical Sciences, Via U. Bassi 58/B, 35121, Padova, Italy
- Italian National Research Council Institute of Neuroscience, University of Padova, Via U. Bassi 58/B, 35121, Padova, Italy
| | - Cristina Paradisi
- Department of Chemical Sciences, University of Padova, Via F. Marzolo 1, 35131 Padova, Italy
| | - Andrea Mattarei
- Department of Chemical Sciences, University of Padova, Via F. Marzolo 1, 35131 Padova, Italy
| | - Marco Pirazzini
- Department of Biomedical Sciences, Via U. Bassi 58/B, 35121, Padova, Italy
| |
Collapse
|
48
|
Azzolini M, Mattarei A, La Spina M, Marotta E, Zoratti M, Paradisi C, Biasutto L. Synthesis and Evaluation as Prodrugs of Hydrophilic Carbamate Ester Analogues of Resveratrol. Mol Pharm 2015; 12:3441-54. [DOI: 10.1021/acs.molpharmaceut.5b00464] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Michele Azzolini
- Department of Biomedical Sciences, University of Padova, viale G. Colombo
3, 35131 Padova, Italy
- NÓOS Srl, via Campello sul Clitunno 34, 00181 Roma, Italy
| | - Andrea Mattarei
- Department
of Chemical Sciences, University of Padova, via Marzolo 1, 35121 Padova, Italy
| | - Martina La Spina
- Department of Biomedical Sciences, University of Padova, viale G. Colombo
3, 35131 Padova, Italy
| | - Ester Marotta
- Department
of Chemical Sciences, University of Padova, via Marzolo 1, 35121 Padova, Italy
| | - Mario Zoratti
- Department of Biomedical Sciences, University of Padova, viale G. Colombo
3, 35131 Padova, Italy
- CNR Neuroscience Institute, viale G. Colombo 3, 35131 Padova, Italy
| | - Cristina Paradisi
- Department
of Chemical Sciences, University of Padova, via Marzolo 1, 35121 Padova, Italy
| | - Lucia Biasutto
- Department of Biomedical Sciences, University of Padova, viale G. Colombo
3, 35131 Padova, Italy
- CNR Neuroscience Institute, viale G. Colombo 3, 35131 Padova, Italy
| |
Collapse
|
49
|
Biasutto L, Mattarei A, Sassi N, Azzolini M, Romio M, Paradisi C, Zoratti M. Improving the efficacy of plant polyphenols. Anticancer Agents Med Chem 2015; 14:1332-42. [PMID: 24975033 DOI: 10.2174/1871520614666140627150054] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2013] [Revised: 02/19/2014] [Accepted: 06/29/2014] [Indexed: 11/22/2022]
Abstract
Plant polyphenols exhibit potentially useful effects in a wide variety of pathophysiological settings. They interact with proteins such as signalling kinases, transcription factors and ion channels, and modulate redox processes, such as those taking place in mitochondria. Biomedical applications of these natural compounds are however severely hindered by their low bioavailability, rapid metabolism, and often by unfavourable physico-chemical properties, e.g. a generally low water solubility. Derivatives are under development with the aim of improving their bioavailability and/or bioefficacy. Various strategies can be adopted. An increase in circulating blood levels of non-metabolized natural compound may be attainable through prodrugs. In the ideal prodrug, phenolic hydroxyls are protected by capping groups which a) help or at least do not hinder permeation of epithelia; b) prevent conjugative modifications during absorption and first-pass through the liver; c) are eliminated with opportune kinetics to regenerate the parent compound. Moreover, prodrugs may be designed with the goals of modulating physical properties of the parent compound, and/or changing its distribution in the body. A more specific action may be achieved by concentrating the compounds at specific sites of action. An example of the second approach is represented by mitochondria-targeted redox-active polyphenol derivatives, designed to intervene on radical processes in these organelles and as a tool either to protect cells from oxidative insults or to precipitate their death. Mitochondrial targeting can be achieved through conjugation with a triphenylphosphonium lipophilic cation. Quercetin and resveratrol were chosen as model polyphenols for these proof-of-concept studies. Data available at the moment show that both quercetin and resveratrol mitochondria-targeted derivatives are pro-oxidant and cytotoxic in vitro, selectively killing fast-growing and tumoural cells when supplied in the low μM range; the mechanism of ROS generation appears to differ between the two classes of compounds. These approaches are emerging as promising strategies to obtain new efficient chemopreventive and/or chemotherapeutic drugs based on polyphenols derivatives.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Mario Zoratti
- CNR Neuroscience Institute, Viale G. Colombo 3, 35121 Padova, Italy.
| |
Collapse
|
50
|
|